Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation  by Nixon, John et al.
Pharmacology & Therapeutics 169 (2017) 57–77
Contents lists available at ScienceDirect
Pharmacology & Therapeutics
j ourna l homepage: www.e lsev ie r .com/ locate /pharmtheraAssociate editor: L. MurrayMonoclonal antibody therapy for the treatment of asthma and chronic
obstructive pulmonary disease with eosinophilic inﬂammationJohn Nixon a, Paul Newbold b, Tomas Mustelin b, Gary P. Anderson c, Roland Kolbeck b,⁎
a MedImmune Ltd., Cambridge, UK
b MedImmune LLC, Gaithersburg, MD, USA
c Lung Health Research Centre, University of Melbourne, Melbourne, Victoria, AustraliaAbbreviations: ACQ-5, Asthma Control Questionnaire
hyper-responsiveness; AQLQ, AsthmaQuality of Life Quest
CCL11, CC-chemokine ligand11; CCL13, CC-chemokine liga
ligand 26; CCR, chemokine receptor; CCR3, Chemokine (C-
pulmonary disease; CTL, cytotoxic T lymphocyte; DC, dend
fragment antigen-binding; Fc, fragment crystallizable; Fcγ
forced expiratory volume in 1 s; FGF, ﬁbroblast growth fa
growth factor receptor 2;HMGB1, high-mobility groupbox
G1; IgG2, immunoglobulin G2; IgG4, immunoglobulin G
interleukin-4 receptor α; IL-5, interleukin-5; IL-5R, inter
interleukin-33; ILC, innate lymphoid cell; ILC2, innate lymp
C4; LTD4, leukotriene D4; LTE4, leukotriene E4; mAb, m
chemoattractant protein 4; MOA, mechanism of action;
PGD2, prostaglandinD2; PDGF, platelet-derivedgrowth fact
scFv, single-chain variable fragment; SGRQ, St. George's Re
chain variable fragment; TGF, transforming growth facto
endothelial growth factor; VEGF-A, vascular endothelial g
⁎ Corresponding author at: MedImmune LLC, One Med
E-mail address: KolbeckR@medimmune.com (R. Kolbe
http://dx.doi.org/10.1016/j.pharmthera.2016.10.016
0163-7258/© 2016 AstraZeneca. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 20 October 2016 Eosinophils have been linked with asthma for more than a century, but their role has been unclear. This review
discusses the roles of eosinophils in asthma and chronic obstructive pulmonary disease (COPD) and describes
therapeutic antibodies that affect eosinophilia. The aims of pharmacologic treatments for pulmonary conditions
are to reduce symptoms, slow decline or improve lung function, and reduce the frequency and severity of
exacerbations. Inhaled corticosteroids (ICS) are important in managing symptoms and exacerbations in asthma
and COPD. However, control with these agents is often suboptimal, especially for patients with severe disease.
Recently, new biologics that target eosinophilic inﬂammation, used as adjunctive therapy to corticosteroids,
have proven beneﬁcial and support a pivotal role for eosinophils in the pathology of asthma. Nucala®
(mepolizumab; anti-interleukin [IL]-5) and Cinquair® (reslizumab; anti-IL-5), the second and third biologics
approved, respectively, for the treatment of asthma, exempliﬁes these new treatment options. Emerging
evidence suggests that eosinophils may contribute to exacerbations and possibly to lung function decline for a
subset of patients with COPD. Here we describe the pharmacology of therapeutic antibodies inhibiting IL-5 or
targeting the IL-5 receptor, as well as other cytokines contributing to eosinophilic inﬂammation. We discuss
their roles as adjuncts to conventional therapeutic approaches, especially ICS therapy, when disease is
suboptimally controlled. These agents have achieved a place in the therapeutic armamentarium for asthma
and COPD and will deepen our understanding of the pathogenic role of eosinophils.




Chronic obstructive pulmonary disease
Cytokines
Eosinophils
Interleukins-5; ACQ-6, Asthma Control Questionnaire-6; ADCC, antibody-dependent cell-mediated cytotoxicity; AG, antigen; AHR, airway
ionnaire; B, B cell; Bas, basophil; BrO−, hypobromite; C1q, complement component 1, subcomponent q; CCL, chemokine ligand;
nd13; CCL17, CC-chemokine ligand17; CCL22, CC-chemokine ligand22; CCL24, CC-chemokine ligand24; CCL26, CC-chemokine
CMotif) Receptor 3; CD, cluster of differentiation protein; CDC, complement-dependent cytotoxicity; COPD, chronic obstructive
ritic cell; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; Eos, eosinophil; EPO, eosinophil peroxidase; Fab,
RIIIa, fragment crystallizable gamma receptor IIIa; FEG, free extracellular granules; FeNO, fractional exhaled nitric oxide; FEV1,
ctor; GINA, Global Initiative for Asthma; GM–CSF, granulocyte-macrophage colony-stimulating factor; HER2, human epidermal
protein 1;H2O2, hydrogenperoxide; ICS, inhaled corticosteroids; IFN, interferon; IgE, immunoglobulin E; IgG1, immunoglobulin
4; IgM, immunoglobulin M; IL, interleukin; IL-3, interleukin-3; IL-3R, interleukin-3 receptor; IL-4, interleukin-4; IL-4Rα,
leukin-5 receptor; IL-5Rα, interleukin-5 receptor α; IL-11, interleukin-11; IL-13, interleukin-13; IL-25, interleukin-25; IL-33,
hoid cell, type 2; ILR, interleukin receptor; LABA, long-acting β2 agonist; LT, leukotriene; LTB4, leukotriene B4; LTC4, leukotriene
onoclonal antibody; Mac, macrophage; MAC, membrane-attack complex; MBP, major basic protein; MCP-4, monocyte
mRNA, messenger ribonucleic acid; NGF, nerve growth factor; NK, natural killer; O2, superoxide; OCS, oral corticosteroids;
or; PGE2, prostaglandin E2; PMN, polymorphonuclear cell; RANTES, regulated on activation, normal T cell expressed and secreted;
spiratory Questionnaire; TARC, thymus- and activation-regulated chemokine; TCR, T-cell receptor; Th2, T-helper 2; scFv, single-
r; TGFβ1, transforming growth factor β1; TNF, tumor necrosis factor; TSLP, thymic stromal lymphopoietin; VEGF, vascular
rowth factor A.
Immune Way, Gaithersburg, MD 20878, USA. Tel.: +1 301 398 5646; fax: +1 301 398 8646.
ck).
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
58 J. Nixon et al. / Pharmacology & Therapeutics 169 (2017) 57–77Contents1. Asthma and chronic obstructive pulmonary disease with eosinophilic inﬂammation . . . . . . . . . . . . . . 58
2. The eosinophilic granulocyte . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3. Pathologic functions of eosinophils . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4. Clinical need in asthma and chronic obstructive pulmonary disease with eosinophilic inﬂammation . . . . . . . 59
5. Potential of therapeutic antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
6. Developmental therapeutic antibodies that target eosinophils . . . . . . . . . . . . . . . . . . . . . . . . 59
7. Future directions for anti-eosinophilic therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
8. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Conﬂict of interest statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62










721. Asthma and chronic obstructive
pulmonary disease with eosinophilic inﬂammation
1.1. Asthma
Asthma is one of the most common chronic diseases, with an
estimated 300 million patients afﬂicted by this disease worldwide. The
Global Initiative for Asthma (GINA) 2004 estimated that more than
10% of the population in Australia, Brazil, Canada, New Zealand, Peru,
England, and United States had asthma. The prevalence of asthma is
expected to increase, and theremay be an additional 100million people
with asthma by 2025 (Masoli et al., 2004). A 2012 survey revealed that
25.5 million people in the United States alone, including 6.8 million
children younger than 18 years, had a diagnosis of asthma (Centers for
Disease Control and Prevention, 2015). Moreover, asthma prevalence
has increased from 3.1% in 1980 (Moorman et al., 2007) to 8.3% in
2012 (Centers for Disease Control and Prevention, 2014).
Thewidespreaduse of inhaled corticosteroids (ICS) asmonotherapy,
and particularly as combination therapy with long-acting β2-agonists
(LABA), has been accompanied by a marked reduction in the burden
of disease and a substantial reduction in asthma mortality (Chauhan
et al., 2015; Chong et al., 2015). However, as with most pharmacother-
apies, population data with ICS or ICS–LABA combinations display a
Gaussian distribution, with a substantial percentage of patients
responding suboptimally or not at all. Furthermore, poor adherence to
medication plays an important role in treatment failure (Gamble et al.,
2009). By deﬁnition, as the requirement for treatment increases, so
does the severity of the disease (Global Initiative for Asthma, 2016). In
its worst form, severe refractory asthma –which affects 3.6% of patients
with asthma – accounts for a disproportionately high burden of
suffering and health care costs (Hekking et al., 2015). Suboptimal
control in these patients manifests as daytime symptoms, nighttime
awakenings, and increased propensity to suffer more frequent and
more severe exacerbations, which, in extreme cases, can be fatal.
Increasingly, experts recognize that moderate to severe asthma is a
disease encompassing several distinct endotypes characterized by the
shared presence of cellular and molecular biomarkers. Linking asthma
endotypes with clinical phenotypes has greatly advanced our under-
standing of asthma pathobiology and the development of novel
targeted therapeutics (Anderson, 2008). For more details on this
subject, we refer the reader to the reviews by Wenzel, 2012, 2013,
2016; Lötvall et al., 2011. One of the best-characterized endotypes of
asthma is the patient population with eosinophilic airway inﬂamma-
tion, which accounts for approximately 40–60% of patients with severe
asthma (Wenzel et al., 1999; Douwes et al., 2002; Zhang & Wenzel,
2007; Schleich et al., 2013).
Several important observations in human initially supported the
hypothesis that eosinophils play a critical role in the pathogenesis and
severity of asthma. An increased eosinophil count is associated with
increased asthma severity, frequency of exacerbations and mortality in
patients with asthma (Bousquet et al., 1990; Tran et al., 2014; Zeigeret al., 2014). A 1995 report quantiﬁed the risk of dying from asthma as
7.4-times greater for patients with eosinophilia than without eosino-
philia (Ulrik & Frederiksen, 1995). Several studies have demonstrated
that sputum eosinophils increase during exacerbations and that
increased numbers of eosinophils in the peripheral blood and airways
of patients with asthma correlate with disease severity. Perhaps most
importantly, persistent, eosinophilic airway inﬂammation increases
the risk of subsequent exacerbations (Jatakanon et al., 2000; Louis
et al., 2000; Di Franco et al., 2003; Miranda et al., 2004; Wenzel, 2005;
Scott & Wardlaw, 2006; Zhang & Wenzel, 2007; Malinovschi et al.,
2013; Schleich et al., 2014). For example,markers of eosinophilic airway
inﬂammation increase well before the onset of exacerbations induced
by corticosteroid withdrawal, and sputum eosinophil number predicts
loss of asthma control after corticosteroid reduction or discontinuation
(Pizzichini et al., 1999; Jatakanon et al., 2000; Deykin et al., 2005). In
addition, activated eosinophils, recognizable by degranulation and
upregulation of biochemical effector pathways, are found in the airways
of patients who have died of acute severe asthma. Necropsy results
identiﬁed two distinct pathogenic inﬂammatory mechanisms of fatal
asthma (Restrepo & Peters, 2008). Patients dying suddenly exhibit a
neutrophilic airway inﬁltrate, whereas postmortem examination of
patients who exhibit more protracted asthma crises, which precipitate
80–85% of all fatal events, reveals an intense eosinophilic inﬁltrate
(James et al., 2005; Restrepo & Peters, 2008).
Another line of evidence comes from the partial success of eosino-
phil management strategies with corticosteroids. The English general
physician Harry Morrow Brown is credited with making the initial
observation that only patientswith asthmawith eosinophilic inﬂamma-
tion responded to oral steroids (Brown, 1958), which was soon after-
ward extended to the ﬁrst effective inhaled steroid, beclomethasone
dipropionate (Brown et al., 1972; Brown & Storey, 1973). A more
comprehensive study demonstrated that a strategy aimed at managing
sputum eosinophils through the controlled use of corticosteroids
achieved a greater reduction in the number of severe exacerbations
for patients withmoderate to severe asthma than a traditional manage-
ment strategy based on British Thoracic Society guidelines (Green et al.,
2002a). More recent studies aimed at controlling sputum eosinophils
through adjustments in ICS have provided similar beneﬁts (Chlumský
et al., 2006; Jayaram et al., 2006). Although these studies do not prove
a cause and effect relationship, as the beneﬁts of controlled corticoste-
roid management may be mediated through different mechanisms,
the ﬁndings lend validity to eosinophilic airway inﬂammation being a
surrogate marker for exacerbation frequency. It is unclear how cortico-
steroids reduce eosinophilic inﬂammation. Some studies suggest that
corticosteroids reduce IL-5 receptor (IL-5R) expression on eosinophils,
rendering them less responsive to IL-5. Other studies propose that
corticosteroids increase eosinophil apoptosis and stimulate phagocytic
elimination of apoptotic eosinophils (Her et al., 1991; Meagher et al.,
1996; Liu et al., 1999).
These initial discoveries in humans of a pathogenic role for eosino-
phils in asthma were conﬁrmed by application of mouse genetics. Two
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provocation with reduced collagen deposition, airway smooth muscle
accumulation, airway hyper-responsiveness (AHR), and mucus hyper-
secretion (Humbles et al., 2004; Lee et al., 2004). Mice deﬁcient in IL-5
or IL-5 receptor-α (IL-5Rα) respond similarly, highlighting the roles of
IL-5 and IL-5Rα as critical pathways for eosinophil development, differ-
entiation, expansion, and activation (Foster et al., 1996; Tanaka et al.,
2004). These ﬁndings were both strain- and model-dependent.
Finally, the most recent and conclusive evidence for a pathogenic
role of eosinophils in asthma comes from therapeutic antibodies that
either antagonize IL-5 (mepolizumab and reslizumab) or have been
engineered to eliminate eosinophils via antibody-dependent cell-
mediated cytotoxicity (ADCC; benralizumab) in patients with
inadequately controlled asthmawith eosinophilic inﬂammation despite
the use of medium- to high-dosage ICS and β-agonists. All three
antibodies reduce eosinophilic inﬂammation to various degrees, which
has been demonstrated to correlate with reduction in acute exacerba-
tions and improvement in lung function and asthma control in some
studies. These therapies are discussed in Section 6 (Haldar et al., 2009;
Nair et al., 2009; Castro et al., 2011, 2014, 2015; Pavord et al., 2012;
Bel et al., 2014; Ortega et al., 2014; Nowak et al., 2015).
1.2. Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) describes a group of
progressive, debilitating respiratory conditions, including emphysema
and chronic bronchitis, characterized by difﬁculty in breathing, airﬂow
limitation, cough, and other symptoms. In contrast with asthma,
irreversible airﬂow obstruction, caused by structural damage to the
elastic microstructure of lung parenchyma and small airway remodel-
ing, is a key COPD feature. COPD affects approximately 380 million
people worldwide, it is the fourth greatest cause of mortality globally
and predicted to become the third by 2020 (Adeloye et al., 2015).
COPD is overwhelmingly associated with a history of cigarette or pipe
smoking. However, with increasing exposure to air pollution and poor
indoor air quality – compounded by other insults that retard lung
growth in utero and in the early years of life – as much as 40% of the
population-attributable risk for COPD is now thought to be independent
of cigarette smoke exposure (WorldHealthOrganization, 2014a, 2014b;
Lange et al., 2015).
COPD is a disease with predominantly neutrophilic inﬂammation of
the airways, and disease pathogenesis involves neutrophils, together
with CD8+ T cells and macrophages. Nevertheless, approximately
20–40% of patients with COPD have elevated eosinophils in their
airways, some despite treatment with ICS (Saha & Brightling, 2006).
The relationship between eosinophilic inﬂammation and disease
severity in COPD is unclear, with some cross-sectional studies reporting
negative correlations between eosinophil numbers and FEV1 (Balzano
et al., 1999; Lams et al., 2000), while others have reported no relation-
ship between eosinophilia and COPD disease severity (Hogg et al.,
2004). However, patients with COPD who have elevated blood or
sputum eosinophil counts were more responsive to corticosteroid
therapy (Saetta et al., 1994; Zhu et al., 2001; Saha & Brightling, 2006).
Treatment with oral corticosteroids may reduce the numbers of
circulating and sputum eosinophils in these patients and reduced the
frequency of severe exacerbations (deﬁned as worsening of respiratory
symptoms resulting in hospital admission) by approximately 62% (Siva
et al., 2007). This phenomenon may account for the beneﬁcial effects
of corticosteroids for a subgroup of patients in a disease that is other-
wise substantially resistant to steroid therapy. Conﬁrmation of this
hypothesis will require the use of therapeutics that speciﬁcally target
eosinophils. Given that ICS therapies are linked with increased
dosage-proportional risk of pneumonia in COPD, there is even greater
interest in non-steroid eosinophil-directed treatment. In a clinical
Phase IIa study of 101 patients with COPD and elevated sputum eosino-
phil counts, benralizumab, a humanized, afucosylated, anti-IL-5Rαmonoclonal antibody, depleted sputum and blood eosinophils and
basophils by enhanced antibody-dependent cell-mediated cytotoxicity.
For these patients, benralizumab had no effect on exacerbations but
signiﬁcantly improved FEV1 in comparison with placebo (Brightling
et al., 2014). Phase III clinical studies are currently underway with
benralizumab (NCT02138916, NCT02155660) and mepolizumab (anti-
IL-5; NCT02105948, NCT02105961), addressing safety and efﬁcacy in
these patients. In addition, one Phase III study with mepolizumab has
recently completed (NCT01463644).
2. The eosinophilic granulocyte
2.1. Eosinopoiesis
Eosinophils are terminally differentiated granulocytes with
the properties of cytotoxic effector cells. Eosinophils develop in bone
marrow derived from CD34+ pluripotent hematopoietic stem cells.
Human eosinophil lineage-committed progenitor cells express the
interleukin-5 receptor (IL-5R) and are direct descendants of IL-5Rα+
myeloid progenitors, distinct from granulocyte–macrophage progeni-
tors that give rise to neutrophils and basophils. Eosinophil progenitors
undergo differentiation in bone marrow where they are exposed to
IL-3, granulocyte-macrophage colony-stimulating factor (GM–CSF),
and IL-5. Of these factors, IL-5 plays a leading role in promoting expan-
sion of the eosinophil lineage from committed progenitors in the bone
marrow (Lopez et al., 1986, 1988; Shalit et al., 1995; Mori et al., 2009).
Eosinophils emerge fully differentiated into the blood stream,where
they have a relatively short half-life of approximately 18 h owing to
their rapid migration into tissues. In healthy individuals, eosinophils
make up approximately 1–5% of circulating leukocytes and populate
peripheral mucosal tissues, such as the gastrointestinal tract, female
reproductive organs, and lymphoid tissues. Eosinophils also develop
from CD34+ progenitor cells outside the bone marrow, notably in
lung tissue. Mobilization of CD34+ progenitors from bone marrow to
the lungs occurs in mouse models of allergic airway inﬂammation
(Southam et al., 2005) and in patients with asthma (Robinson et al.,
1999a; reviewed by Gauvreau & Denburg, 2005). Progenitors in the
lungs may differentiate into mature eosinophils depending on the
local tissue environment and under the inﬂuence of soluble factors
such as IL-5, IL-3, GM–CSF, thymic stromal lymphopoietin (TSLP),
IL-33, leukotrienes and CC chemokine ligand 11 (CCL11; eotaxin-1)
(Dorman et al., 2004a, 2004b; Allakhverdi et al., 2009; Smith et al.,
2015). Anti-IL-5 treatment in humans with mepolizumab induced
only partial maturational arrest of the eosinophil lineage in the bone
marrow, a reduction in airway CD34+/IL-5Rα mRNA+ cell numbers
(Menzies-Gow et al., 2003), and a partial reduction of mature tissue
eosinophils in patients with asthma (Flood-Page et al., 2003a; Haldar
et al., 2009). These observations demonstrate that, in humans, factors
other than IL-5 contribute to the differentiation and survival of eosino-
phils in the bone marrow and pulmonary mucosa. Thus, inhibiting
IL-5 alone may not be adequate to eliminate tissue eosinophils rapidly.
2.2. Eosinophil granules
When ﬁrst described by Paul Ehrlich in 1878, the eosinophil was so
named because of the exuberant staining of its speciﬁc secondary gran-
ules with the red dye eosin (Ehrlich, 1878). Human eosinophil-speciﬁc
secondary granules are a store of diverse, preformed cationic proteins.
They contain four major proteins: eosinophil peroxidase (EPO), major
basic protein (MBP), and the ribonucleases, eosinophil cationic protein
(ECP) and eosinophil-derived neurotoxin (EDN), but also store several
cytokines, enzymes, and growth factors. Other prominent features
of eosinophils include primary granules containing Charcot–Leyden
crystal protein (galectin 10, eosinophil lysophospholipase) and lipid
bodies, which are sites of synthesis of cysteinyl leukotrienes, eoxins,
thromboxane, and prostaglandins.
60 J. Nixon et al. / Pharmacology & Therapeutics 169 (2017) 57–77Eosinophils release their granule products in three different ways:
cytolysis, exocytosis, and piecemeal degranulation. When eosinophils
die by lysis, they liberate intact, membrane-bound free extracellular
granules (FEGs) (Neves & Weller, 2009; Lacy & Moqbel, 2012).
Receptor-mediated activation of these FEGs results in secretion
of selected granule-derived proteins. Although FEGs are present in
human disease, their pathological signiﬁcance is the subject of active
debate (see discussion in Section 3 below; Persson & Uller, 2014).
Eosinophil exocytosis, through which intracellular granules fuse
with the plasma membrane to release their entire contents, tends to
occur principally in response to parasites, on the surfaces of large,
multicellular helminths.
Eosinophils can also selectively discharge distinct mediators, even
though these are actually co-stored in the same secretory granules,
by a process termed piecemeal degranulation, ﬁrst reported by Ann
Dvorak (Dvorak et al., 1991; Melo & Weller, 2010). In this process,
distinct from classical exocytosis, secretory granules maintain their
integrity because fusion events among granules and between granules
and the plasma membrane do not occur. Piecemeal degranulation is
themost commonly observed physiologic form of eosinophil degranula-
tion. The identiﬁcation of these granule products in blood offers the
possibly of developing biomarker panels that may reﬂect eosinophil
number and activity state.2.3. Host defense
Phylogenetically, eosinophils are ancient and predate the develop-
ment of T cells. The T-cell/eosinophil nexus likely arose under selection
pressure from helminthic parasites. Reports of the antiparasitic features
of eosinophils occur as far back as 1939. Helminths are parasitic worms
that typically induce a T-helper 2 (Th2) immune response in their
hosts, promoting immunoglobulin E (IgE) responses and eosinophilia.
Peripheral and tissue eosinophilia and increased blood concentrations
of eosinophil-derived granule proteins occur in helminth-infected indi-
viduals. In vitro, eosinophils can attach to the surface of helminth larvae
(Shin et al., 2001), release damaging granule contents (Hamann et al.,
1990), and kill worms in antibody- and complement-dependent fashion
(Butterworth et al., 1975; Rainbird et al., 1998; Shin et al., 2001). How-
ever, in vivo, the picture is more complicated. For example, in humans,
the 434CC polymorphism, resulting in a less cytotoxic formof the eosin-
ophil granule protein ECP, is more common among Ugandans, who live
in a region endemic for infection by the parasitic helminth Schistosoma
mansoni (Eriksson et al., 2007). By contrast, the 434CC genotype is quite
rare in Sudan, where S. mansoni is not endemic, suggesting no selective
disadvantage for individuals with the 434CC polymorphism to mount
anti-schistosomal host defense (Eriksson et al., 2007). Interestingly,Fig. 1. (a) Eosinophilic inﬂammation in asthma and COPD. Allergens, pathogens, cigarette smo
activation and injury of airway epithelial cells. Epithelial cells release damage-associated mol
or amplify airway inﬂammation. Depending on the quality and combination of stimuli, a varie
cells, dendritic cells, macrophages, ILC2, basophils, neutrophils). Consequently, adaptive im
B cells. In combination, the innate and adaptive immune cells are the source of mediators th
BrO−, H2O2), lipid mediators (LTB4, LTC4, LTD4, LTE4, eoxins, thromboxane), cytokines (IL-1α
differentiation factors (TGFβ, VEGF, NGF, FGF, PDGF), proteases (elastase), chemokines (CCL11,
(PGD2, PGE2), immunoglobulins (IgE), and histamine. Together, these cells and their mediat
hypersecretion and epithelial hyperplasia, all associated with clinical sequelae of asthma and
chemokines (CCL11, CCL24, CCL26, RANTES), lipids (LTB4), cytokines (GM–CSF, IL-3, IL-4, IL-5,
Eosinophils are a rich source of a large number of mediators, including basic granule proteins
monoclonal antibodies for asthma and COPD. Monoclonal antibodies in clinical development
indicated. The red T-shaped symbols indicate the molecular target of the respective antibody
is the only ADCC-enhanced antibody resulting in target cell apoptosis, symbolized by the red
(basophil), BrO− (hypobromite), CD (cluster of differentiation protein), CCL (chemokine lig
(cytotoxic T lymphocyte), DC (dendritic cell), ECP (eosinophil cationic protein), EDN (eosino
growth factor), GM–CSF (granulocyte-macrophage colony-stimulating factor), H2O2 (hyd
(immunoglobulin E), IL (interleukin), ILC (innate lymphoid cell), IL-4Rα (interleukin-4 recep
LTD4 (leukotriene D4), LTE4 (leukotriene E4), Mac (macrophage), MBP (major basic protein), N
growth factor), PGD2 (prostaglandin D2), PGE2 (prostaglandin E2), PMN (polymorphonuclear c
protein), TCR (T-cell receptor), Th (T-helper cell), TGF (transforming growth factor), TNF (tumor
factor).carriers of the 434CC genotype develop substantially less liver ﬁbrosis
secondary to S. mansoni infection (Eriksson et al., 2007), pointing to
the potential of ECP to cause tissue injury in vivo. This study and other
studies in humans suggest the importance of inducing an effective
antihelminthic eosinophil responsewhileminimizing collateral damage
to affected tissues. The questionable importance of eosinophils in the
host response to parasites has been corroborated by the variable out-
comes of eosinophil suppression inpreclinical animalmodels of parasite
infection (Sher et al., 1990; Herndon & Kayes, 1992; Shin et al., 1997;
Betts & Else, 1999). Overall, the role of eosinophils in parasite infections
remains unclear and may be parasite-dependent.
Eosinophils have also been implicated in the host response to
respiratory viral infections in preclinical models of respiratory syncytial
virus (Domachowske et al., 1998; Phipps et al., 2007) and parainﬂuenza
infections (Adamko et al., 1999). Indeed, eosinophilia has been reported
in experimental human rhinovirus-16 infection studies in healthy
individuals and patients with asthma, and human respiratory viruses
(most prominently rhinoviruses) are among the more common causes
of asthma exacerbations (Fraenkel et al., 1995; Grünberg et al., 1997;
Jackson et al., 2014). The fact that respiratory viruses are a common
cause of exacerbations in asthma, combined with the observation that
biologics targeting the IL-5 and IL-5Rα pathways lead to decreased
eosinophilic inﬂammation and decreased frequency of exacerbations,
to varying degrees, argues for a dispensable role of eosinophils in viral
host defense under such circumstances.2.4. Drivers of eosinophil recruitment and activation
Although IL-5 is the primary regulator of eosinophil migration into
the circulation, additional cytokines and chemokines contribute to
directing eosinophil migration into inﬂamed tissues. Nevertheless, IL-5
does play a particularly important role in eosinophil recruitment.
It synergizes with other Th2 cytokines, IL-4 and IL-13, and with the
eosinophil chemo-attractants, CCL11, CCL24 and CCL26, to promote
eosinophil activation and recruitment into tissues in acute inﬂammatory
responses (Collins et al., 1995; Mould et al., 1997; Foster et al., 2001;
Pease & Williams, 2001). However, other mediators also play a signiﬁ-
cant role in recruiting eosinophils to sites of inﬂammation. Among
these are the cytokines TSLP, IL-25, and IL-33, which structural cells
release in response to various environmental insults. TSLP, IL-25, and
IL-33 are distinct cytokines with signiﬁcant overlapping biology and a
common function in promoting Th2 responses. In the airways, these
three early cytokines target a range of similar cell types; and all promote
eosinophilic inﬂammation, at least in part by inducing IL-5 production
and by amplifying Th2 responses (Allakhverdi et al., 2007; Neill et al.,
2010; Mjosberg et al., 2011; Ikutani et al., 2012; Kim et al., 2013a,ke, toxins, and other particulate matter accumulate in the airway lumen and result in the
ecular pattern molecules (HMGB1) and innate cytokines (IL-33, IL-25, TSLP) that initiate
ty of innate immune cells are recruited and activated in the lung (e.g., eosinophils, mast
mune responses are initiated, exempliﬁed by the accumulation and activation of T and
at amplify inﬂammation in many different ways, including reactive oxygen species (O2−,
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CCL17, CCL22, CCL24, CCL26, RANTES, IL-8), Charcot-Leyden crystal protein, prostaglandins
ors also drive airway hyperresponsiveness and constriction, airway remodeling, mucus
COPD. Eosinophils are a key inﬂammatory cell whose persistence is directly regulated by
IL-13, IL-25, IL-33, TSLP), and damage-associated molecular pattern molecules (HMGB1).
(MBP, ECP, EPO, EDN) that are toxic and can injure neighboring tissues. (b) Therapeutic
that have been demonstrated to affect eosinophilic inﬂammation in asthma or COPD are
, which is shown in brown, and its antagonistic activity against the target. Benralizumab
X.Abbreviations: ADCC (antibody-dependent cell-mediated cytotoxicity), B (B cell), Bas
and), CCR (chemokine receptor), COPD (chronic obstructive pulmonary disease), CTL,
phil-derived neurotoxin), Eos (eosinophil), EPO (eosinophil peroxidase), FGF (ﬁbroblast
rogen peroxide), HMGB1 (high-mobility group box 1 protein), IFN (interferon), IgE
tor α), IL-5Rα (interleukin-5 receptor α), LTB4 (leukotriene B4), LTC4 (leukotriene C4),
GF (nerve growth factor), NK (natural killer cell), O2– (superoxide), PDGF (platelet-derived
ell = neutrophil), RANTES (regulated on activation, normal T cell expressed and secreted
necrosis factor), TSLP (thymic stromal lymphopoietin), VEGF (vascular endothelial growth
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delays apoptosis of eosinophils (Wong et al., 2010), whereas IL-33 po-
tently activates murine eosinophils and increases the survival of
human eosinophils (Cherry et al., 2008; Wen et al., 2013).
In addition, growth factors such as GM–CSF (Woolley et al., 1995;
Simon et al., 1997;Wang et al., 2007; Griseri et al., 2015) andmolecules
with an alarmin function such as high-mobility groupprotein 1 (HMGB1)
can also recruit and activate eosinophils, but they appear to act indepen-
dently of IL-5. Further research in this area may help better understandthe mechanisms by which eosinophils are activated, in particular in
response to damage-associated molecular pattern molecules such as
HMGB1 (Lotﬁ et al., 2007; Rosenberg et al., 2013). These molecules
may play a signiﬁcant role in eosinophil recruitment associated with
nonpulmonary conditions such as myalgias and myopathies.
Fig. 1 provides themain structural and hematopoietic cells and their
secreted factors that orchestrate the recruitment, differentiation, activa-
tion, andmaintenance of eosinophils in the airways of asthma andCOPD
patients. For additional reading about the biology of eosinophils in host
62 J. Nixon et al. / Pharmacology & Therapeutics 169 (2017) 57–77defense and disease, we would like to direct the reader to two excellent
and comprehensive reviews (Rothenberg & Hogan, 2006; Rosenberg
et al., 2013).
3. Pathologic functions of eosinophils
Pathologic conditions of the lung can lead to the increase in eosino-
phil production in the bone marrow and the migration of these cells
along chemokine or cytokine gradients into the lung, where they
contribute to the manifestation of clinical phenotypes. Eosinophils can
contribute to pulmonary inﬂammation through several mechanisms.
A key action is through the release of cytotoxic granule-associated
basic proteins, reactive oxygen species, and lipid mediators, which
collectively can damage surrounding cells and induce AHR and mucus
hypersecretion. Bronchial biopsies from patients with asthma indicate
an association between eosinophil numbers and epithelial damage
(Wilson et al., 2013), and eosinophil granule proteins are cytotoxic
toward epithelial cells in vitro. In addition, eosinophils are an important
source of mediators of airway narrowing, such as leukotriene C4, and
eosinophil degranulation has been linked to AHR in animal models
and humans.
Signiﬁcant lysis of eosinophils can occur in asthmatic airways,
releasing free eosinophilic granules into bronchial tissue. The evidence
for eosinophil lysis in bronchial tissues and its part in damaging the
airways was recently reviewed (Persson & Uller, 2014). Transmission
electronmicrographs of asthmatic airway tissues demonstrate “spilling”
of FEGs from lytic eosinophils and immunostaining for toxic granule
proteins shows FEGs in numerous asthmatic bronchi. In contrast, there
are few signs of eosinophil apoptosis in these tissues (Uller et al.,
2006). FEGs occur strikingly in some instances of lethal asthma, but
few intact eosinophils are present (Filley et al., 1982) and FEGs are
clearly increased in sputum at severe exacerbations (Pizzichini et al.,
1997). In addition, studies have suggested an association between the
presence of FEGs, rather than intact eosinophils, and epithelial disrup-
tion in asthmatic airways (Filley et al., 1982; Woolley et al., 1995;
Fattahi et al., 2013; Volbeda et al., 2013). These studies suggest that
therapeutics directed at suppressing eosinophilic inﬂammation should
do so by mechanisms that avoid eosinophil lysis and degranulation.
Eosinophils also have an important role in promoting both the
recruitment and activation of Th2 cells in the lungs, and this process
potentially occurs through multiple mechanisms. Eosinophils release
preformed cytokines, such as IL-4 and IL-13, that amplify Th2 responses
(Spencer et al., 2009). They also release Th2-type chemoattractants,
such as CCL17 and CCL22, which promote recruitment of Th2 T cells
(Jacobsen et al., 2008). Eosinophils may also have an antigen-
presenting function. Although they are not “professional” antigen-
presenting cells, eosinophils do express cell surface molecules needed
for antigen presentation. They can process antigens and stimulate T
cells in an antigen-speciﬁc manner, resulting in T-cell proliferation
and cytokine release (Wang et al., 2007).
Eosinophils can interact directly or indirectly with other innate cell
populations tomaintain and enhance a Th2 environment. These interac-
tions currently are not very well-deﬁned, but they may also contribute
to tissue remodeling processes such as ﬁbrosis. Eosinophilic inﬁltrates
and eosinophil granule proteins are present in ﬁbrotic tissues from
many different organs, including the lungs, and are associated with
rapid disease progression in patientswith idiopathic pulmonary ﬁbrosis
(Fujimoto et al., 1995; Birring et al., 2005). In asthma, eosinophils could
contribute to subepithelial ﬁbrosis through generation of proﬁbrotic
mediators such as transforming growth factor beta 1 (TGFβ1) and
IL-11; and several reports claim that the majority of TGFβ1 mRNA-
positive cells in bronchial biopsies of patients with severe asthma are
eosinophils (Minshall et al., 1997; Vignola et al., 1997; Flood-Page
et al., 2003b). Human eosinophils cultured with ﬁbroblasts augment
the contraction of 3-dimensional collagen matrices (Zagai et al., 2004),
and crosstalk between mast cells and eosinophils may inﬂuenceﬁbroblast behavior in allergic inﬂammation (Elishmereni et al., 2011).
Functional evidence also comes from in vivo studies in eosinophil-
deﬁcientmice that demonstrated decreased airway extracellularmatrix
deposition following allergen challenge (Humbles et al., 2004). Obser-
vations in patients with asthma corroborate these ﬁndings. Eosinophil
suppression via anti-IL-5 treatment (mepolizumab) in patients with
mild atopic asthma resulted in reduced deposition of extracellular
matrix proteins in the bronchial subepithelial basement membrane
(Flood-Page et al., 2003b) and, in a subsequent study in patients with
severe eosinophilic asthma, in reduced airway-wall thickness and
total wall area (Haldar et al., 2009). Whether and how eosinophil-
mediated ﬁbrosis of the airways contributes to the pathogenesis of
asthma or other diseases characterized by eosinophilic inﬂammation
remains to be determined.
Fig. 1 depicts some of the main products of activated eosinophils
in the airways, which contribute to airway damage and which are
associated with pathophysiologic alterations and inﬂammation.
4. Clinical need in asthma and chronic obstructive
pulmonary disease with eosinophilic inﬂammation
Most asthma guidelines include a stepwise approach to treatment
whereby control is achieved by stepping up treatment as necessary.
Inhaled corticosteroids (ICS), ﬁrst introduced in the early 1970s, are
the cornerstone of treatment for asthma, improving lung function, and
reducing symptoms and exacerbations (Rodrigo, 2006).
Early studies of ICS did not focus particularly on eosinophilic
asthmatics, although several studies suggested that the presence of
persistent airway eosinophilic inﬂammation seemed to be a good
predictor of short-term response to ICS. Many studies have indicated
that continual treatment with ICS rapidly reduces sputum eosinophilia
(Fahy & Boushey, 1998; Jatakanon et al., 1998; Meijer et al., 1999; van
Rensen et al., 1999; Aldridge et al., 2000).
Early studies of patients with eosinophilic and non-eosinophilic
asthma investigating short-term ICS treatment were small and not
placebo-controlled (Lim et al., 1999; Pavord et al., 1999; Green et al.,
2002b; Jang et al., 2005; Bacci et al., 2006). The ﬁrst randomized
controlled trial compared 8 weeks' treatment with ICS in patients with
eosinophilic vs. non-eosinophilic asthma and demonstrated better
improvement in airway hyper-responsiveness andhealth-related quality
of life for eosinophilic patients (Berry et al., 2007). Subsequently,
Woodruff et al. demonstrated that lung function improvements with
ICS were restricted to Th2-high asthma patients, a phenotype that
included patients with elevated blood and airway eosinophilia
(Woodruff et al., 2009). In a larger study, McGrath et al. found that
low-dosage ICS (4–6 weeks of treatment) achieved good asthma con-
trol for a greater percentage of mild to moderate asthma patients who
were eosinophilic (sputum eosinophils N 2%) than non-eosinophilic
asthma patients (McGrath et al., 2012).
Several studies have investigated long-term treatment with ICS
therapy for eosinophilic asthma patients. Three randomized controlled
trials of patients with moderate to severe asthma have demonstrated
that normalizing airway eosinophil numbers by titrating ICS for approx-
imately 1 year signiﬁcantly reduced the frequency and severity of
asthma exacerbations when compared with just following treatment
guidelines (Green et al., 2002a; Chlumský et al., 2006; Jayaram et al.,
2006). However, there is a paucity of large, long-term studies directly
comparing the beneﬁts of ICS treatment on asthma control for eosino-
philic versus non-eosinophilic patients.
Despite the effectiveness of ICS in treating exacerbations for many pa-
tientswith eosinophilic asthma, a subset of patients have persistent tissue
eosinophilia despite receiving high-dosage ICS and oral corticosteroids
(Synek et al., 1996; Jatakanon et al., 1999; Louis et al., 2000; ten Brinke
et al., 2001; Miranda et al., 2004). Approximately one-half to two-thirds
of patients with difﬁcult-to-treat asthma are estimated to also have per-
sistent tissue eosinophilia despite receiving high-dose ICS or oral
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suggesting the presence of a distinct steroid-resistant eosinophilic pheno-
type (Wenzel et al., 1999). Yet, themolecularmechanisms contributing to
“corticosteroid-resistant” eosinophilic inﬂammation are unclear.
Persistent corticosteroid usage has other limitations and, in particu-
lar, is associated with signiﬁcant adverse effects (Elixhauser & Owens,
2007; Manson et al., 2009; Sarnes et al., 2011). Long-term treatment
with high-dosage ICS is associated with systemic adverse effects
(Pandya et al., 2014), including reduced bone mineral density (Wong
et al., 2000; Israel et al., 2001; Kelly, 2003;Monadi et al., 2015) associated
with osteoporotic fractures. Oral corticosteroids cause signiﬁcantly
greater morbidity, and high dosages of oral corticosteroids needed to
partially control severe asthma in some patients frequently contribute
to signiﬁcant adverse effects, such as coronary heart disease, psychiatric
comorbidities, osteoporosis, diabetes and pneumonia (Iribarren et al.,
2012; Amelink et al., 2014; Zazzali et al., 2015).
Nonadherence to ICS is a signiﬁcant reason for poor asthma control,
asthma-related emergency visits and hospitalizations, and increased
oral steroid use (Williams et al., 2004; Gamble et al., 2009; Murphy
et al., 2012). Even for refractory patients with persistent symptoms,
poor long-term adherence to ICS regimens is still an issue (Gamble
et al., 2009;Wuet al., 2015). In addition, nonadherence to short-term cor-
ticosteroid therapy (inhaled or systemic) is surprisingly common for
adult asthmatics discharged from the emergency department or hospital
after initial therapy for acute asthma and is a key factor associated with
relapse (Krishnan et al., 2004; Williams et al., 2004). Nonadherence to
short-term treatment with oral corticosteroids following discharge from
the emergency department has been associated with poor outcomes for
some pediatric patients with persistent asthma (Cooper & Hickson,
2001; Butler & Cooper, 2004; Williams et al., 2013).
Despite the advent of newer and effective therapies, many patients
with COPD continue to have exacerbations and deterioration of lung
function and quality of life. Hence, a substantial need remains for
improving lung function, achieving better symptom control, reducing
exacerbations, slowing disease progression, and improving life expec-
tancy (Calverley, 2008). The use of inhaled corticosteroids in combina-
tion with other medications, such as long-acting beta agonists, has
been associated with an improvement in exacerbation rates and
health-related quality of life in patients with COPD (Global Initiative
for Chronic Obstructive Lung Disease, 2016). It is not clear which
patients beneﬁt the most from inhaled corticosteroids, but it is clear
that the response is heterogeneous. In ameta-analysis of 12 randomized
controlled trials (comprising 1331 patients with acute exacerbations of
COPD treated with systemic corticosteroids), pooled analysis demon-
strated a beneﬁcial effect of treatment. However, when analyzed by
subgroups, treatment beneﬁt was observed only for non-critically ill
patients (those not admitted to intensive care), and no effect on patient
mortality was observed for any group (Abroug et al., 2014). Changes in
sputum cell counts have also yielded heterogeneous results, with
numbers of neutrophils, eosinophils, and macrophages demonstrated
to be unaltered or reduced following corticosteroid therapy (Saha &
Brightling, 2006). More speciﬁc and effective therapeutic agents
directed at eosinophilic inﬂammation may provide additional options
for some patients who do not appear to respond adequately to cortico-
steroid therapy.
Thus, the clinical need in patient populationswith asthma and COPD
with eosinophilic inﬂammation presents an ideal opportunity for the
development of biologic long-acting therapies that more completely
and selectively suppress airway eosinophilic inﬂammation.
5. Potential of therapeutic antibodies
During the last 30 years, therapeutic antibody development has
blossomed, with the realization that these agents offer high speciﬁcity
and afﬁnity for molecular targets that are frequently intractable to
small-molecule approaches. This rapid progress has seen biologicsbecome a mainstay of therapeutic options for patients with autoim-
mune and inﬂammatory diseases. For example, sales of the tumor
necrosis factor antagonist adalimumab reached $10 billion, making it
the biggest-selling drug for that year (King, 2014).
Efﬁcacy of early murine or human/mouse chimeric antibodies was
limited by development of immunogenicity in patients. Thus, most an-
tibodies now entering clinical trials have been humanized or are fully
human antibodies, which generally yield much reduced immunogenic-
ity. Many therapeutic antibodies work by binding and neutralizing
their molecular targets through their variable Fab domains, while their
Fc domains are engineered to be “immunologically silent” (Fig. 2a–c).
Examples discussed in this review include anti-IgE (omalizumab,
ligelizumab), anti-IL-5 (mepolizumab, reslizumab), anti-IL-13
(tralokinumab, lebrikizumab), anti-TSLP (AMG157/MEDI-9929), anti-
CCL11 (bertilimumab), and anti-IL-4Rα (dupilumab; see Fig. 1b and
Table 1). Improvements in binding afﬁnity are routinely achieved
through a range of optimization strategies generating, in some cases,
monoclonal antibodies with exquisitely high afﬁnities for their target
antigens (Finch et al., 2011; Lowe et al., 2011). Alternatively, a therapeu-
tic antibody can highly selectively bind an antigen on the surface of
target cells while its Fc domain can actively engage complement or
immune cells, resulting in the selective elimination of these target
cells via complement-dependent cytotoxicity (CDC) or ADCC, respec-
tively (Fig. 2d,e and Table 1). The anti-IL-5Rα antibody benralizumab
is an example of an ADCC-enhancing antibody that induces cell death
of IL-5Rα-expressing eosinophils and basophils.
Therapeutic antibodies typically have long serum half-lives, which
allow for infrequent administration, every otherweek or less frequently
(Roopenian & Akilesh, 2007; Finch et al., 2011; Robbie et al., 2013;
Souders et al., 2015), an advantage in situations in which the targeted
patient population adheres poorly to standard of care. Systemic
administration can intravenous or subcutaneous, the latter potentially
allowing the convenience of self-administration for patients with
chronic diseases. Inhaled delivery of therapeutic antibodies is particu-
larly relevant for pulmonary indications to optimize drug delivery to
the luminal surfaces of the airways or to avoid systemic safety issues.
However, this route of administration presents challenges, such as
residence time of therapeutic antibodies in the lung and delivery of
antibodies across themucus barrier and to the lower airways. Although
several inhaled therapeutic proteins are either in late-stage clinical
development (e.g., α-1 anti-trypsin [AAT; Kamada]) or approved and
marketed (e.g., DNase for cystic ﬁbrosis [dornase alfa; Pulmozyme®;
Genentech]), there are not yet any marketed, inhaled therapeutic
antibodies.
The high potency and speciﬁcity of therapeutic antibodies for partic-
ular molecular targets is a major advantage in maximizing their clinical
efﬁcacy and limiting their adverse effects. However, they are frequently
reserved for patients with more severe manifestations of diseases who
consume considerable health care resources. Improving the under-
standing of the different molecular mechanisms underpinning patient
heterogeneity in a disease such as asthma allows the identiﬁcation of
key molecular targets for different patient subpopulations and the
tailoring of therapeutic antibody treatments to those patients most
likely to respond, thus maximizing the value of each therapy.
Polypharmacy is often required to optimize therapy for complex
indications. Therapeutic antibodies are often an adjunct to current
standard of care, providing additional beneﬁt for patientswhose disease
is insufﬁciently controlled with approved medications, which could
apply to patients with poorly controlled asthma and COPD. Combining
therapeutic antibody treatments may be a viable option. Co-
administration of two separate therapeutic antibodies in the clinical
setting allows dosing ﬂexibility, but it may be an advantage to combine
therapies in a single vial or even a single molecule (bispeciﬁc antibodies,
Fig. 2g). The emergence of alternative formats and improvements in gen-
erating and producing bispeciﬁc antibodies have driven a resurgence of
interest in thisﬁeld (Kontermann&Brinkmann, 2015; Spiess et al., 2015).
Fig. 2. (a) Monoclonal antibody domain structure. A monoclonal antibody molecule consists of two heavy (H) chains and two light (L) chains that together form an Fab region and an Fc
region. The Fab region of the antibody forms a site (paratope) that binds a site (epitope) on a speciﬁc antigen. Properties of the Fc region determine whether the antibody will engage the
effector functions of neighboring cells and also its half-life. (b–e) Therapeutic antibodies have different modes of action. A monoclonal antibody can speciﬁcally bind to and neutralize a
soluble (b) ormembrane-associated antigen (c). For this function, it is usually desirable tominimize the effector properties of the Fc region. Amonoclonal antibody can also bind an antigen
speciﬁcally expressed on a pathological target-cell population and engage effector cells (e.g., NK cells) via bindingof its Fc region to Fcγ receptors (e.g., FcγRIIIa) on the effector cell (d). This
triggers production of enzymes from the effector cell that cause death of the target cell. Therapeutically, thismechanism can be utilized to deplete selected pathogenic cell populations. An
alternativemechanism to induce target cell death is complement-mediated cytotoxicity (CDC), which engages complement C1q through the “classical pathway”, leading to the formation
of themembrane-attack complex (MAC) (e). (f)Mouse, chimeric, humanized, and humanmonoclonal antibodies. Theﬁrst therapeuticmonoclonal antibodieswere generated frommouse
cells. Chimeric antibodies have a mixture of mouse (gray) and human (mauve) sequences. In humans, mouse and chimeric antibodies can prime the body's immune system to destroy
them, resulting in reduced efﬁcacy on repeated treatment. In humanized antibodies, the only murine sequences retained are those directly involved in antigen recognition; but many
monoclonal antibodies now entering clinical trials are fully human. Humanized and human monoclonal antibodies are associated with far fewer immunogenic responses. (g) Bispeciﬁc
formats. Two plausible formats are provided for a bispeciﬁc antibody that speciﬁcally binds two unrelated antigens. In both formats, one antigen (red) binds via the main antibody
framework. Binding of the second antigen (pink) occurs via a single-chain variable fragment (scFv) linked to the main antibody framework at variable locations. Abbreviations: C1q
(complement component 1, subcomponent q), Fab (fragment antigen-binding), Fc (fragment crystallizable), FcγRIIIa (fragment crystallizable gamma receptor IIIa), MAC (membrane-
attack complex), NK (natural killer cell), TNF (tumor necrosis factor), HER2 (human epidermal growth factor receptor 2), scFv (single-chain variable fragment).
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6.1. Anti-IL-5 and anti-IL-5Rα
From the choices available, the IL-5 and IL-5Rα pathways appear an
obvious approach for selectively targeting eosinophilic inﬂammation in
patients with asthma and COPD. IL-5 is a homodimeric cytokine
secreted predominantly by T cells, mast cells, eosinophils, basophils,
and the recently described Type 2 innate lymphoid cells (ILC2). TheIL-5R comprises an IL-5Rα chain, selectively expressed on eosinophils
and basophils, and a common βc-chain, which it shares with the recep-
tors for IL-3 and GM–CSF (Geijsen et al., 2001; Murphy & Young, 2006).
IL-5 binds IL-5Rα subunit with low afﬁnity, but dimerization of IL-5Rα
and βc-subunits generates a high-afﬁnity receptor complex required
to transduce intracellular signals upon IL-5 binding (Tavernier et al.,
1991; Milburn et al., 1993; Dickason & Huston, 1996; Dickason et al.,
1996; Rossjohn et al., 2000). IL-5 is the only cytokine that binds
IL-5Rα and activates the high-afﬁnity IL-5R.
Table 1














Kd = 7.7 nM
(Arm et al., 2014)
Sputum:
• Reduction post allergen challenge but not statistically
signiﬁcant compared with placebo (Fahy et al., 1997)
• Reduction in patients with mild to moderate allergic
asthma (Djukanović et al., 2004)
• Nonsigniﬁcant reduction compared with placebo in
patients with severe allergic asthma (Takaku et al.,
2013)
Lung tissue:
• Statistically signiﬁcant reduction in lung tissue eosino-
phils in patients with mild to moderate asthma
(Djukanović et al., 2004) and in patients with severe
allergic asthma (Riccio et al., 2012)
Blood:
• Reduction in blood eosinophils post allergen challenge
(Fahy et al., 1997) and in patients with moderate to
severe allergic asthma (Massanari et al., 2010)
Statistically signiﬁcant reduction in the number of
asthma exacerbations, improvements in lung function
and symptoms for patients with moderate to severe








• Reduction post allergen challenge in patients with
mild asthma (Leckie et al., 2000)
• Reduction in patients with severe asthma with eosino-
philic inﬂammation (Haldar et al., 2009; Nair et al.,
2009; Pavord et al., 2012)
BAL:
• Reduction (Flood-Page et al., 2003b)
Lung tissue:
• Reduction in tissue eosinophils in patients with mild asth-
ma (Flood-Page et al., 2003b) and patients with severe
asthma with an eosinophilic inﬂammation (Haldar et al.,
2009)
Blood:
• Reduction in patients with mild allergic asthma (Leckie et
al., 2000; Flood-Page et al., 2003b) and in patients with
severe asthma with eosinophilic inﬂammation (Haldar
et al., 2009; Nair et al., 2009; Pavord et al., 2012; Ortega
et al., 2014)
Bone marrow:
• Reduction (Flood-Page et al., 2003b)
Statistically signiﬁcant reduction in exacerbations,
improvement in FEV1, ACQ-5, and SGRQ for patients
with severe, uncontrolled asthma with eosinophilic








Kd = 81 pM
(Walsh, 2013)
Sputum:
• Reduction in patients with moderate to severe asthma
(Castro et al., 2011)
Blood:
• Reduction in blood eosinophils (Kips et al., 2003; Cas-
tro et al., 2015)
Statistically signiﬁcant reductions in exacerbations and
improvements in lung function, ACQ and AQLQ for
patients with severe asthma with eosinophilic









• Reduction in patients with mild to moderate asthma
(Laviolette et al., 2013)
Lung tissue:
• Reduction in patients with mild to moderate asthma
(Laviolette et al., 2013)
Blood:
• Reduction in patients with mild (Busse et al., 2010),
mild to moderate (Laviolette et al., 2013) and moder-
ate to severe asthma (Castro et al., 2014)
Bone marrow:
• Reduction in patients with mild to moderate asthma
(Laviolette et al., 2013)
Statistically signiﬁcant reductions in exacerbations and
improvements in lung function, asthma symptoms,
ACQ-6 and AQLQ in patients with moderate to severe,
uncontrolled asthma with eosinophilic inﬂammation by
blood eosinophils ≥ 300/μL (Castro et al., 2014;
Bleecker et al., 2016; FitzGerald et al., 2016)
Lebrikizumab Anti-IL-13 Humanized IgG4




• Increase in patients with moderate to severe uncon-
trolled asthma (Corren et al., 2011; Hanania et al.,
2015)
Statistically signiﬁcant reduction in exacerbations and
improvement in lung function for patients with moderate
to severe asthma and greater concentrations of serum
periostin. High blood eosinophils at baseline (≥240/μL)
were also predictive of efﬁcacy (Hanania et al., 2015)
Tralokinumab Anti-IL-13 Fully human IgG4 Sputum: Statistically signiﬁcant reduction in exacerbations and
(continued on next page)







Effect on eosinophils Clinical effects
Kd = 165 pM
(May & Fung.,
2015; May et al.,
2012; Monk et al.,
2005)
• No detectable effect in patients with moderate to se-
vere asthma (Piper et al., 2013)
Blood:
• Increase in blood eosinophils in patients with moder-
ate to severe asthma (Piper et al., 2013; Brightling
et al., 2015a)
improvements in lung function, ACQ-6 and AQLQ for
patients with severe asthma with high serum periostin
or dipeptidyl peptidase 4 (Brightling et al., 2015)
Dupilumab Anti-IL-4Rα Fully human IgG4




• Overall increase in blood eosinophils in patients with
moderate to severe asthma which did not reach statis-
tical signiﬁcance (Wenzel et al., 2013)
Reduction in exacerbations, improvement in lung
function, ACQ-5 and asthma symptom score for patients
with moderate to severe asthma with eosinophilic
inﬂammation while tapering ICS therapy (Wenzel et al.,
2013)






• Reduction post allergen challenge in patients with
mild asthma (Gauvreau et al., 2014)
Blood:
• Reduction pre and post allergen challenge in patients
with mild asthma (Gauvreau et al., 2014)
Currently in Phase II evaluating the efﬁcacy in patients




Kd = 80 pM
(Main et al.,
2006)
No clinical data to date No clinical data to date
Abbreviations: ACQ-5, Asthma Control Questionnaire-5; ACQ-6, Asthma Control Questionnaire-6; ADCC, antibody-dependent cell-mediated cytotoxicity; AQLQ, Asthma Quality of Life
Questionnaire; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; IgE, immunoglobulin E; IgG1, immunoglobulin G1; IgG2, immunoglobulin G2; IgG4, immunoglobulin
G4; IL-5, interleukin-5; IL-5Rα, interleukin-5 receptor α; MOA, mechanism of action; SGRQ, St. George's Respiratory Questionnaire.
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eosinophil lineage; it is strongly involved in all stages of eosinophil
development, as well as many aspects of eosinophil pathobiology
(Sanderson, 1992; Rådinger & Lötvall, 2009), making it an attractive
target for an anti-eosinophil biologic. It plays a central part in differenti-
ation and maturation of eosinophils in bone marrow, and IL-5 priming
induces eosinophil locomotor activity, suggesting that it might play a
role in eosinophil recruitment to inﬂamed pulmonary tissues (Sehmi
et al., 1992;Wen et al., 2013; Larose et al., 2014). IL-5 stimulates activa-
tion and degranulation of eosinophils; enhances their survival in tissues
(Ochiai et al., 1997; Huang et al., 2005); and promotes eosinophilic
precursors to proliferate, differentiate and function independently in
various tissues, including the lung (Robinson et al., 1999a, 1999b; Lu
et al., 2010; Dorman et al., 2004a, 2004b; Rådinger & Lötvall, 2009;
Fulkerson et al., 2014). IL-5 expression is elevated in bronchoalveolar
lavage ﬂuid and bronchial biopsies from asthmatic patients with eosin-
ophilic pulmonary inﬂammation (Hamid et al., 1991; Kim et al., 2003;
Huang et al., 2005). Inhalation of IL-5 by patients with asthma causes
sputum eosinophilia and airway hyper-responsiveness (Shi et al.,
1998).
Despite the clear association of IL-5 and eosinophils with asthma,
developing IL-5-directed therapeutics has proven much more difﬁcult
than originally anticipated. In particular, the early clinical trial results
with IL-5-directed mAbs in “all-comers” asthma trials proved to be
extremely disappointing (Leckie et al., 2000; Flood-Page et al., 2003a,
2007; Kips et al., 2003). Nevertheless, careful subpopulation responder
analysis has led to the identiﬁcation that severe asthma patients with
evidence of eosinophilic inﬂammation in the airway have marked
reduction in eosinophilic inﬂammation and clinical beneﬁts when
treated with an anti-IL-5 monoclonal antibody (Haldar et al., 2009;
Nair et al., 2009). Therefore, IL-5 is an important cytokine contributing
to eosinophilic inﬂammation in these patients.
Mepolizumab (Nucala®; SB-240563; GSK) is a humanized mAb of
the immunoglobulin IgG1/kappa isotype with dosage-proportional
pharmacokinetics and a terminal half-life of approximately 21 days in
patients with asthma. Maximum plasma concentrations occurred
0.5–4.8 h following infusion, and mepolizumab was well-absorbed
(Smith et al., 2011). An early allergen challenge study of patients withmild asthma who received mepolizumab demonstrated pronounced
long-term suppression of circulating eosinophils and signiﬁcantly
lowered sputum eosinophils, but had no effect on the allergen-
induced early or late asthmatic response or histamine-induced AHR
(Leckie et al., 2000). A separate study conducted in patients with mild,
controlled, atopic asthma evaluated the effect of mepolizumab on
eosinophil numbers and eosinophil activation products in the lung
tissue. In this study, 3 months of treatment with mepolizumab induced
substantial reductions of eosinophils in blood, bronchoalveolar lavage
ﬂuid, and bone marrow. However, the median reduction in mucosal
airway eosinophils was only 55%, and eosinophil activation products
in the lung tissue were similar in patients treated with mepolizumab
compared with placebo. Interestingly, the investigators reported no
signiﬁcant effect of mepolizumab on number of basophils, the only
other cell-type in human expressing the IL-5R and responding to IL-5
(Denburg et al., 1991), in the lung tissue. In addition, 3 months of treat-
mentwithmepolizumab had no statistically signiﬁcant effect compared
with placebo on any of the clinical endpoints measured (Flood-Page
et al., 2003a). Treatment with mepolizumab resulted in a statistically
signiﬁcant reduction in extracellular matrix protein deposition com-
pared with placebo, suggesting eosinophils may contribute to airway
tissue remodeling (Flood-Page et al., 2003b). In a larger study conducted
in patients with asthma and persistent symptoms despite ICS therapy,
mepolizumab treatment did not signiﬁcantly improve clinical end-
points (e.g., FEV1, β-agonist use, symptom score, exacerbation rates),
although there was a not statistically signiﬁcant numerical decrease in
exacerbation rates in the group receiving the greatest mepolizumab
dosage. Thus, mepolizumab treatment did not appear to add signiﬁcant
clinical beneﬁt in patients with asthma whose symptoms persisted
despite corticosteroid therapy, although it suggested the need for
further studies on exacerbation rates (Flood-Page et al., 2007). However,
these early clinical trials did not preselect patients with eosinophilic
airway inﬂammation, and they largely focused on clinical outcomes
not closely associated with eosinophilic airway inﬂammation.
A major breakthrough came with two small proof-of-concept
studies demonstrating that treatment with mepolizumab reduced the
risk of exacerbations in patients with severe, refractory eosinophilic
asthma and a history of severe exacerbations. In these studies,
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least 3%. In the ﬁrst study, mepolizumab treatment resulted in a 2-fold
reduction in lung tissue eosinophils and a signiﬁcant 43% (95% CI
8–68%) reduction in the annual exacerbation rate comparedwith place-
bo, but had no signiﬁcant effects on symptoms, FEV1, or AHR (Haldar
et al., 2009). This key ﬁnding was conﬁrmed in the second smaller
study (Nair et al., 2009) conducted in prednisone-dependent patients
with asthma and sputum eosinophilia. Ten of 11 patients who had re-
ceived placebo experienced asthma exacerbations, compared with 1 of
9 patients who received 5 monthly infusions of mepolizumab
(750 mg). Patients receiving mepolizumab were able to reduce their
daily dosages of prednisone by a mean of 83.8% of their maximum pos-
sible dosages, while maintaining efﬁcacy. The much larger 621-patient
DREAM clinical trial corroborated these initial ﬁndings with
mepolizumab in patients with severe, uncontrolled asthma and evi-
dence of eosinophilic inﬂammation (peripheral blood eosinophil count
of at least 300/μL; Pavord et al., 2012). The annual number of clinically
signiﬁcant exacerbations per patient was reduced by 48% (95% CI
31–61%) in patients who had received mepolizumab 75 mg intrave-
nously every 4weeks comparedwith placebo, accompanied by a reduc-
tion in blood eosinophil counts (geometric mean ratio compared with
placebo (0.22 [0.18–0.27]). The utility of measuring blood eosinophil
counts is of particular note, for early work had suggested that it might
be necessary to determine eosinophil counts in sputum, lavage, or
lung biopsy, all of which are impractical in usual clinical practice outside
of specialist research centers.
All tested mepolizumab dosages (75 mg, 250mg, and 750 mg intra-
venously) signiﬁcantly reduced the number of exacerbations and time
to ﬁrst exacerbation, whereas the effects of mepolizumab on secondary
endpoints of FEV1 andACQ(AsthmaControl Questionnaire) scoreswere
generally similar to placebo. The differential effects of mepolizumab on
exacerbations, lung function, and day-to-day clinical manifestations of
asthma (FEV1, ACQ scores) prompted a discussion of the extent to
which these manifestations are mechanistically distinct features of
severe asthma patient populations. Although the DREAM study did
not demonstrate improvement in FEV1 or ACQ scores, theMepolizumab
as Adjunctive Therapy in Patients with Severe Asthma (MENSA) Phase
III trial (Ortega et al., 2014) demonstrated improvement in both of
these parameters. Compared with placebo, 100-mg subcutaneous
mepolizumab demonstrated improvements in FEV1 of 98 mL (95% CI
11–184) and ACQ-5 score of −0.44 (−0.63 to −0.25), as well as a
relative reduction in annual exacerbation rate of 53% (36–65). In this
Phase III trial, eosinophilic inﬂammation was deﬁned as a peripheral
blood eosinophil count of at least 150/μL at screening or a historic
eosinophil count of at least 300/μL in the previous 12 months. A post-
hoc analysis of data from the DREAM and MENSA studies reported a
relationship between baseline blood eosinophil count and clinical efﬁ-
cacy of mepolizumab (Ortega et al., 2016). Reductions in exacerbation
rates with mepolizumab increased with baseline eosinophil count,
from 52% (95% CI 42–61) for patients with a count of at least 150/μL to
70% (60–77) for patients with a count of at least 500/μL.
A recent review of eight mepolizumab randomized clinical trials
involving 1707participants,which included theMENSA study, concluded
that patients with severe asthma with eosinophilic inﬂammation
receiving mepolizumab had reduced exacerbations and improved
health-related quality of life (Powell et al., 2015). However, this review
concluded that there was no signiﬁcant beneﬁt on lung function, asthma
symptom scores, cough scores, or AHR.
Despite its demonstrable neutralization of IL-5, mepolizumab does
not completely deplete eosinophils in the airway mucosa in patients
with either mild to moderate or severe asthma (Flood-Page et al.,
2003a; Haldar et al., 2009). This may be explained by the fact that, in
humans, eosinophil survival factors other than IL-5, such as GM–CSF
are involved in tissue survival (Simon & Blaser, 1995; Youseﬁ et al.,
1996; Simon et al., 1997; Shen & Malter, 2015). GM–CSF enhances
eosinophil survival in allergic nasal polyps. GM–CSF mRNA, not IL-5mRNA, is increased in individuals with non-allergic chronic sinusitis
and nasal polyps, and tissue eosinophilia has a stronger correlation
with GM–CSF thanwith IL-5 expression. In patients with allergic chron-
ic sinusitis and nasal polyps, eosinophilia had a stronger correlation
with GM–CSF and IL-3 expression than with IL-5 expression (Hamilos
et al., 1993; Hamilos et al., 1995). Thus, strategies that deplete eosino-
phils more profoundly than anti-IL-5 treatments may prove to be even
more effective.
The Food and Drug Administration and the European Medicines
Agency approved mepolizumab in late 2015. In the United States,
mepolizumab is indicated for the add-on maintenance treatment of
patients with severe asthma aged 12 years and older andwith an eosin-
ophilic phenotype, and, in Europe, is indicated as an add-on treatment
for severe refractory eosinophilic asthma in adult patients (Nucala
European Union Summary of Product Characteristics, 2015; Nucala
Package Insert, 2015). Mepolizumab is currently being studied in
three Phase III clinical trials in patients with COPD with eosinophilic
airway inﬂammation (NCT01463644, NCT02105948, NCT02105961).
Reslizumab (Cinquair®; SCH55700; Teva) is a humanized rat anti-
IL-5 mAb of the immunoglobulin IgG4/kappa subtype. The terminal
half-life for reslizumab is 24.5–30.1 days, with the maximal concentra-
tion obtained 6.9 h after dosing (Kips et al., 2003). The clinical develop-
ment path of reslizumab started on a similarly disappointing note as
that of mepolizumab. In an early clinical study, treatment with a single
dose of reslizumab reduced circulating eosinophils but provided no
overall signiﬁcant improvement in lung function (FEV1) and other
clinical indices of disease activity in patients with severe persistent
asthma (Kips et al., 2003). However, in a subsequent clinical trial that
recognized the importance of selecting patients with uncontrolled
asthmawith eosinophilic inﬂammation, reslizumab 3.0mg/kg adminis-
tered every 4 weeks for 12 weeks induced a signiﬁcant improvement in
FEV1 of 0.24 L (95% CI 0.09–0.39) compared with placebo and a non-
statistically signiﬁcant reduction in exacerbations in these patients
(Castro et al., 2011). In two subsequent multicenter Phase III studies,
reslizumab 3.0mg/kg administered every 4weeks for 48weeks demon-
strated improvements compared with placebo for exacerbations (rate
reduction 54% [95% CI 42–63%]), lung function (0.11 L [0.067–0.15]),
ACQ-7 (−0.25 [−0.34 to 0.16]), and health-related quality of life scores
(0.23 [0.16–0.39]) (Castro et al., 2015). Although the improvement in
asthma control and lung function measures were more striking than
those in the mepolizumab DREAM or MENSA studies, this reslizumab
study had a peripheral blood eosinophil count cutoff of at least 400/μL
eosinophils, compared with 150/μL in the mepolizumab studies.
Another study recently found a positive relationship between baseline
blood eosinophil counts and FEV1 improvement at Week 16 with
reslizumab treatment (slope: 0.0229) for patients with poorly
controlled asthma (Corren et al., 2016).
Efﬁcacy differences observed in clinical trials between mepolizumab
and reslizumab are probably not a result of their pharmacologic proper-
ties,which are similar. Both have a high afﬁnity to IL-5,with a dissociation
constant of 100 pM for mepolizumab and 81 pM for reslizumab (Egan
et al., 1995; Hart et al., 2001; Nucala Package Insert, 2015). Both antibod-
ies have low picomolar activity in inhibiting IL-5 activity in cell models
(Egan et al., 1995; Hart et al., 2001; Nucala Package Insert, 2015).
The Food and Drug Administration and the European Medicines
Agency approved reslizumab in March 2016. In the United States,
reslizumab is indicated for add-on maintenance treatment of patients
with severe asthma aged 18 years and older, and with an eosinophilic
phenotype (Cinqair Package Insert, 2016). Reslizumab received a
positive opinion recommending marketing authorization from the
EuropeanMedicines Agency's (EMA) Committee forMedicinal Products
for Human Use (CHMP) in June 2016, and has been submitted to and is
currently under review by Health Canada.
Benralizumab (AstraZeneca, MedImmune) is a humanized,
afucosylatedmonoclonal antibody (IgG1 k) that binds with high afﬁnity
to IL-5Rα and rapidly depletes eosinophils and basophils through ADCC.
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domain, enhancing its ability to bind the main activating human Fcγ-
receptor IIIa (CD16) on natural killer (NK) cells (Kolbeck et al., 2010),
the importance of which has been demonstrated in ADCC assays using
primary human eosinophils and NK cells. In contrast with strategies
such as anti-FAS (CD95) antibodies, which provoke eosinophils to
release free eosinophilic granules (FEGs) that damage tissue (Uller
et al., 2005), eosinophil apoptosis induced by benralizumab is not
associated with eosinophil degranulation in vitro (Kolbeck et al.,
2010). Benralizumab has a mean elimination half-life of approximately
2 to 3 weeks (Busse et al., 2010). Its mean volume of distribution is
greater than the plasma volume, potentially indicating binding to
IL-5Rα cells and/or moderate extravascular tissue penetration (Busse
et al., 2010).
In a Phase I study in patients with asthma, benralizumab given as
single IV doses produced a rapid and nearly complete depletion of
peripheral blood eosinophils persisting for at least 84 days, with
corresponding reductions in serum eosinophil activation products ECP
and EDN (Busse et al., 2010; Pham et al., 2016). A Phase II, multiple-
ascending-dosage safety study in adult patients with asthma using a
subcutaneous formulation of benralizumab conﬁrmed the pharmacoki-
netic and pharmacodynamic properties observed with the IV dosing
study (Gossage et al., 2010). In agreement with in-vitro studies,
benralizumab induced reversible eosinopenia in patients with asthma
without inducing eosinophil degranulation. For patients with mild to
moderate asthma and ≥2.5% sputum eosinophilia despite ICS therapy,
treatment with benralizumab subcutaneously for 3 months demon-
strated substantial depletion of eosinophils in blood, sputum, bone
marrow, and lung tissue (combined 100-mg and 200-mg dosage
groups; Laviolette et al., 2013). In a Phase IIb study of patients with
uncontrolled asthma, benralizumab, given subcutaneously at dosages
up to 100 mg every 8 weeks for 1 year had an acceptable safety proﬁle,
with few serious treatment-related adverse events. Benralizumab
100 mg every 8 weeks reduced the acute exacerbation rate by 41%
(95% CI 11–60) compared with placebo for patients with baseline
blood eosinophils ≥ 300 cells/μL, but patients without eosinophilia did
not exhibit this same beneﬁt. In the cohorts with eosinophilia, all
dosages of benralizumab resulted in improvements in the secondary
endpoints FEV1 and ACQ-6, compared with placebo (Castro et al.,
2014). In a subsequent study, a single dose of benralizumab adminis-
tered in the outpatient setting 7 days after patients presented to the
emergency department with an asthma exacerbation reduced the sub-
sequent asthma exacerbation rate by 49% and exacerbations requiring
hospitalization by 60% compared with placebo (Nowak et al., 2015).
Benralizumab achieved the primary endpoints in two pivotal Phase
III registrational trials (SIROCCO and CALIMA), demonstrating signiﬁcant
reductions in annual asthma exacerbation rates and improved lung
function compared with placebo, and was well-tolerated (Bleecker
et al., 2016; FitzGerald et al., 2016).
A small Phase IIa study evaluated benralizumab in patients with
moderate to very severe COPD, a history of previous exacerbations,
and sputum eosinophilia. Following subcutaneous administration of
benralizumab 100 mg every 8 weeks (after three doses 4 weeks
apart), blood and sputum eosinophils were profoundly depleted from
theﬁrstmeasurement timepoint through1 year of treatment, achieving
much greater eosinophil suppression than in earlier studies of inhaled
or oral corticosteroids (Brightling et al., 2014). Benralizumab did not
meet its primary endpoint, a reduction in exacerbation rate at Week
56 in the overall population. A prespeciﬁed subanalysis indicated that
patients with elevated blood eosinophils (≥200 cells/μL) treated with
benralizumab had a nonsigniﬁcant 31% reduction in COPD exacerbation
rate compared with placebo. Patients with elevated blood eosinophils
also exhibited signiﬁcant improvement in FEV1 (0.29 L; 95% CI
0.02–0.55), whereas patients without elevated eosinophils did not.
These ﬁndings supported further clinical development of benralizumab
to investigate potentially beneﬁcial clinical effects in a subgroup ofpatients with COPD. Two Phase III studies are currently underway in
patients with COPD (NCT02138916, NCT02155660).
6.2. Anti-IL-5/anti-IL-5R antibodies: Are they all the same?
The distinctive mechanisms of actions of benralizumab, which
depletes eosinophils and basophils through enhanced ADCC, and the
IL-5 ligand blocking antibodies mepolizumab and reslizumab may
produce differential ablation of eosinophils in key tissues.
Benralizumab, reslizumab, and mepolizumab all suppress blood
eosinophil counts in patients with asthma. In sputum, benralizumab
and mepolizumab reduce eosinophils to similar degrees. Benralizumab
(100 mg or 200 mg, subcutaneous once monthly) demonstrated a
combined 89.9% decrease in sputum eosinophils at Day 28 (Laviolette
et al., 2013). In the DREAM study, the top dosage of mepolizumab
(750 mg IV once monthly) had a similar high degree of suppression
(88%) at 52 weeks, but with a wide variability (Pavord et al., 2012).
Speed of eosinophil depletion differs in benralizumab vs. mepolizumab.
Benralizumab depletes peripheral blood eosinophils rapidly, with a
peak reduction within 24 h (Laviolette et al., 2013). Mepolizumab
induces a gradual reduction that peaks at 4 weeks after dosing (Flood-
Page et al., 2003a). In addition, the ability of these agents to suppress
bone marrow eosinophils and eosinophil precursors differs. For four
patients with asthma receiving benralizumab, eosinophils and
eosinophil precursors were undetectable in all bone marrow aspirates
(Laviolette et al., 2013). In contrast, three intravenous mepolizumab
dosages resulted in a 52% median reduction in bonemarrow eosinophil
count (Flood-Page et al., 2003a). Differences in study design, study
populations, and eosinophil inclusion criteria between the studies may
have contributed to the different results.
Airway tissue eosinophils are the key effector cells in causing airway
damage, and here signiﬁcant differences emerge between benralizumab
and mepolizumab. Three monthly infusions of 750 mg of intravenous
mepolizumab resulted in a median decrease in airway mucosal eosino-
phil counts of only 55% (Flood-Page et al., 2003a). In a subsequent study,
12monthly intravenous infusions of 750mgofmepolizumab in patients
with severe refractory asthma with sputum eosinophilia also produced
a similar magnitude of reduction in lung tissue eosinophils (Haldar
et al., 2009). In contrast, three subcutaneous benralizumab dosages
(100 mg or 200 mg once monthly) demonstrated a median reduction
of 95.8% in mucosal airway eosinophil counts (Laviolette et al., 2013).
However, the sample size in this study was very small, and this ﬁnding
requires further exploration. The decreased dependence of airway
tissue eosinophils on IL-5 for survival may explain their incomplete
removal by the anti-IL-5 therapy mepolizumab. Activated eosinophils
in the airways of patients with asthma exhibit decreased IL-5Rα surface
expression (Liu et al., 2002a,b; Gregory et al., 2003). Furthermore,
cytokines such as IL-3 and GM–CSF persist in the airways and can aid
tissue eosinophil survival. In animal models of allergy, more effective
eosinophil depletion can be achieved by combining IL-5 inhibition
with blockade of GM–CSF and IL-3 or the eotaxin receptor CCR3
(Nishinakamura et al., 1996; Foster et al., 2001). In contrast,
benralizumab would be expected to cause tissue eosinophil apoptosis
regardless of the presence of eosinophil survival factors. Furthermore,
benralizumab can drive eosinophil apoptosis at low IL-5R densities
because the ADCCmechanism bywhich it works is relatively insensitive
to surface density of target receptors (vanMeerten et al., 2006). Immu-
nohistochemistry studies of lung biopsies from patients with asthma
indicate that benralizumab stains more than 90% of eosinophils,
suggesting that IL-5R receptor density is sufﬁcient for benralizumab
engagement in this key location (Kolbeck et al., 2010). The pronounced
depletion of mucosal airway eosinophils with benralizumab is likely a
result of ADCC decreasing the number of eosinophils available for
trafﬁcking into the lung and directly reducing eosinophil count in the
lung. However, further kinetic studies in patients, with accounting for
lung tissue T½ of eosinophils, would be required to establish the main
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less dependent on IL-5 for survival, but they are still susceptible to the
effects of a highly potent, eosinophil-depleting, anti-IL-5R mAb.
Benralizumab also depletes other potentially pathogenic cell
populations expressing IL-5R, such as basophils, as suggested by in-
vitro studies (Kolbeck et al., 2010). In a small double-blind, placebo-
controlled trial of patients with asthma, median estimates of basophil
countwere reduced by 74% at Day 84, following threemonthly subcuta-
neous doses of benralizumab (Laviolette et al., 2013). Basophils have
been repeatedly implicated in allergic airway disease (Gauvreau et al.,
2000; MacGlashan et al., 2002; Salter et al., 2015), but it is not known
whether the depletion of basophils contributes to the therapeutic
beneﬁt of benralizumab.
The apparent pharmacodynamic differences in the magnitude of
eosinophil depletion in bonemarrow and lung tissue and the additional
effect of benralizumab to deplete basophils are interesting. It is
unknown whether these will translate into differences in the clinical
efﬁcacy of these differentmechanisms of action for patientswith severe,
uncontrolled asthma with eosinophilic inﬂammation, patients with
COPD and eosinophilic inﬂammation, or patients with other diseases
characterized by eosinophilic inﬂammation.
Finally, subcutaneous administrations of benralizumab and
mepolizumab may provide patients with convenience in comparison
with reslizumab, which is currently administered intravenously.
6.3. Anti-IgE monoclonal antibodies
Allergens are key triggers of asthma and, with allergic asthma, a
common phenotype in patients with asthma (Global Initiative for
Asthma, 2016). Allergens, recognized by dendritic cells, lead to activa-
tion of Th2 cells, B-cell proliferation, and IgE production. IgE binds to
the high-afﬁnity IgE receptor, FcεRI, expressed on basophils and mast
cells. Cross-linking of IgE, upon subsequent exposure to speciﬁc
allergens results in activation and degranulation of basophils and
mast cells and release of pro-inﬂammatory cytokines, chemokines,
prostanoids, and peptidyl leukotrienes that can propagate eosinophilic
inﬂammation. Therefore, blocking IgE to prevent this reaction is a
potential mechanism for preventing eosinophilic inﬂammation.
Omalizumab (Xolair®; Roche Genentech and Novartis) is a human-
ized IgG1 anti-IgE mAb that inhibits binding of IgE to its low- and high-
afﬁnity receptors, CD23 and FcεRI, respectively. In patientswith asthma,
it decreases free IgE concentrations and downregulates expression of
high afﬁnity IgE receptors. In 2003, omalizumab became the ﬁrst Food
and Drug Administration–approved biologic for asthma treatment
when it was approved for the treatment of patients with moderate to
severe persistent allergic asthma whose disease is not adequately
controlled by ICS alone. The dosage of omalizumab is complex and
determined by a patient's baseline IgE (IU/ml) and body weight (kg).
Furthermore, the criteria for dosing, based on baseline IgE concentra-
tions, differ in approved territories (Xolair [European Union Summary
of Product Characteristics], n.d.; Xolair, United States package insert,
2014). Omalizumab decreases the rate of asthma exacerbations, annual-
ized rates of hospital admissions, total emergency department visits,
rescue therapy use, and ICS dosage.
Several studies have demonstrated that omalizumab reduces
numbers of peripheral, sputum and bronchial submucosal eosinophils
in patients with asthma and allergies (Fahy et al., 1997; Djukanović
et al., 2004; Massanari et al., 2010; Riccio et al., 2012; Takaku et al.,
2013). Skiepko et al. demonstrated that patients with asthma and
allergies who exhibited a strong reduction in blood eosinophil counts
in response to omalizumab had a lower exacerbation rate in the
subsequent 12 months on treatment (Skiepko et al., 2014). In a much
larger study of patients with uncontrolled asthma with normal lung
function treated with omalizumab, a baseline peripheral eosinophil
count ≥300/μLwas associatedwith a reduction in asthma exacerbations
versus placebo. On the other hand, patients with low baselineeosinophil counts exhibited no improvement in exacerbations (Busse
et al., 2013). Another large study in omalizumab-treated patients with
severe, persistent asthma and allergies reached a similar conclusion
(Hanania et al., 2013). In these studies, patient IgE concentrations
were 30–700 IU/mL (Hanania et al., 2013; Skiepko et al., 2014) or
30–1300 IU/mL (Busse et al., 2013). Collectively, these studies suggest
that omalizumab can suppress eosinophil counts in some patients
with asthma and that patients with greater baseline eosinophils receive
greater beneﬁt from omalizumab therapy. The mechanism by which
anti-IgE suppresses eosinophil recruitment and the extent of airway eo-
sinophil reduction are areas for further investigation that may inform
the potential overlap between anti-IgE and anti-IL-5 therapies. Reduc-
tion in exacerbationswith anti-IL-5 therapy did not correlatewith atop-
ic status or IgE concentrations (Pavord et al., 2012), a ﬁnding that
provides a basis for differentiation between anti-IL-5 and anti-IgE ther-
apies. Nevertheless, a recent study of the National Health and Nutrition
Examination Survey (2005–2006) indicated a signiﬁcant overlap of
eosinophilic and atopic phenotypes in patients with severe asthma
(Tran et al., 2016). Therefore, further researchwill be required to under-
stand which patients may gain optimal treatment beneﬁt from anti-IgE
therapy versus anti-eosinophilic treatment with anti-IL-5 monoclonal
antibodies or benralizumab.
New-generation anti-IgE monoclonal antibodies now in clinical
development may demonstrate more potent effects on IgE concentra-
tions. One such monoclonal antibody is QGE031 (ligelizumab), which
is currently in Phase II clinical trials for asthma (NCT02336425).
6.4. Anti-IL-13 and anti-IL-4Rαmonoclonal antibodies
IL-13 is a Th2 cytokine that enhances mucus production, goblet cell
hyperplasia, smooth muscle cell contraction, airway remodeling, and
AHR (Rael & Lockley, 2011; Corren, 2013). In conjunction with IL-4,
IL-13 generates IgE class switching. Therapeutic antibodies directed
against IL-13 speciﬁcally interfere with the activity of IL-13, whereas IL-
4Rα inhibition antagonizes the activity of both IL-4 and IL-13 because of
the use of this receptor chain by both cytokines. Eosinophils are a source
of IL-4 and IL-13 and respond to IL-4 and IL-13 with activation, survival
and cytokine expression. IL-4 and IL-13 indirectly regulate eosinophils
through their pleiotropic activities on many cell types, which result in
the production of solublemediators and cell surface receptors interacting
with eosinophils. For a comprehensive summary of the pathological activ-
ities and targeting strategies for both cytokines, we would like to direct
the reader to a recent review (May & Fung, 2015).
Tralokinumab (AstraZeneca, MedImmune) is a fully human, IgG4
anti-IL-13 mAb that has entered Phase III clinical trials in asthma
(NCT02161757, NCT02194699, NCT02281357). Tralokinumab was
initially evaluated in 194 patients with moderate to severe, uncon-
trolled asthma at subcutaneous dosages of 150 mg, 300 mg, or 600 mg
every other week for 12 weeks. Tralokinumab failed to affect ACQ-6,
but it dosage-dependently improved FEV1 by 150 mL and reduced
short-acting β agonist use by 0.5 puffs per day compared with placebo.
In a post-hoc analysis, patients who were positive for sputum IL-13
achieved better outcomes than patients who were negative (Piper
et al., 2013). In a subsequent, larger Phase IIb study, tralokinumab at
the greatest dosage evaluated (300 mg subcutaneously every other
week for 52 weeks), did not signiﬁcantly reduce asthma exacerbations
in “all-comers” with severe, uncontrolled asthma, but it demonstrated
a 67% reduction in exacerbation rate in patients with reversible asthma
and high periostin concentrations (Brightling et al., 2015a). At the same
dosage, for patients with high periostin concentrations, tralokinumab
signiﬁcantly improved FEV1 and ACQ-6 versus placebo (Brightling
et al., 2015b). Elevated serum DPP-4 has also been proposed as a
surrogate biomarker of IL-13 pathway activation in the lung, and an
enhanced response to tralokinumab was reported for patients with
high baselineDPP-4 concentrations in this Phase IIb study. Interestingly,
tralokinumab induced elevated blood eosinophil numbers in the study
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severe asthma (Piper et al., 2013), but it did not provide an effect on
sputum eosinophils (Piper et al., 2013). The Phase II MESOS study
(NCT02449473) aims to better understand the mechanism of action
of tralokinumab in improving asthma control and investigate the
hypothesis that tralokinumab inhibits eosinophil elevation in the lung
by interfering with eosinophil trafﬁcking to the lung (Brightling et al.,
2015b).
Periostin is a serum biomarker induced by IL-4 and IL-13 (Yuyama
et al., 2002; Woodruff et al., 2007) in airway epithelial cells that may
successfully predict response of patients with asthma to anti-IL-13
monoclonal antibodies. Hence, in addition to elevated numbers of
eosinophils, periostin represents another useful biomarker to tailor
treatment for patients with uncontrolled severe asthma.
Lebrikizumab (Roche) is a humanized, IgG4, anti-IL-13 mAb
being studied in Phase III clinical trials in asthma (NCT01867125,
NCT01868061, NCT01875003, NCT01987492, NCT02099656,
NCT02104674) and a Phase II study in COPD (NCT02546700). Clinical
trials that included a small, lung-allergen provocation study of patients
with mild asthma also evaluated lebrikizumab. In one study,
lebrikizumab non-signiﬁcantly inhibited the late-phase response by
48% and suppressed serum IgE, CCL13 (MCP-4) and CCL17 (thymus-
and activation-regulated chemokine/TARC) concentrations by approxi-
mately 25% after 12 weeks of 5 mg/kg subcutaneous administrations
(Scheerens et al., 2014). Suppression of these biomarkers, including
fractional exhaled nitric oxide (FeNO), by lebrikizumab is a common
ﬁnding across several clinical studies in patients with mild to poorly
controlled, severe asthma (Corren et al., 2011; Noonan et al., 2013;
Scheerens et al., 2014; Hanania et al., 2015). In a study of steroid-
naïve patients with asthma, lebrikizumab, when dosed subcutaneously
at 125 mg, 250 mg or 500 mg every 4 weeks for 12 weeks, protected
patients from treatment failure (need for ICS/OCS) and modestly
improved FEV1, but it did not affect ACQ. Interestingly, for this patient
population, none of these outcomes was associated with serum
periostin status (Noonan et al., 2013). When studied in 219 patients
with asthma that was uncontrolled despite medium–high dosages of
ICS, 250mg lebrikizumab (subcutaneousmonthly injections) improved
FEV1 by 8.2% and reduced the rate of severe exacerbations by 67% vs.
placebo for patients with high serum periostin (Corren et al., 2011). In
pooled patient cohorts of two subsequent clinical trials in patients
with uncontrolled asthma despite ICS (LUTE and VERSE), lebrikizumab
dosages of 37.5mg, 125mg, and 250mgmonthly reduced the exacerba-
tion rate in patients with high periostin by 81%, 77%, and 22%, respec-
tively (Hanania et al., 2015). However, of two identical Phase III
studies of patients with severe asthma (LAVOLTA I and II), only one
study met its primary endpoint of lebrikizumab treatment signiﬁcantly
reducing exacerbations in the primary population of patients
with periostin ≥ 50 ng/mL or blood eosinophils ≥ 300 cells/μL
(i.e., biomarker-high patients) (Hanania et al., 2016). For these
biomarker-high patients, lebrikizumab did not consistently demon-
strate reductions in asthma exacerbations.
Dupilumab (Sanoﬁ, Phase III) is a fully human, mAb to the IL-4Rα
subunit, and thus blocks both IL-4 and IL-13 signaling. IL-4 is key to
polarization and maintenance of Th2 cells and drives Ig class switching
from IgM to IgE antibodies in B cells. In a Phase IIa study, patients with
asthma on high-dosage ICS/LABA with elevated blood (≥300/μL) or
sputum eosinophils (≥3%) were administered weekly subcutaneous
dosages of 300 mg of dupilumab for 12 weeks (Wenzel et al., 2013).
After Week 4, LABA dosing was discontinued, and after Week 6, ICS
therapies were tapered. Dupilumab treatment resulted in a 210-mL
improvement in FEV1 and a 1.04 improvement in ACQ-5 score, in
contrast with a 20-mL worsening in FEV1 and a 0.66 improvement in
ACQ-5 score for placebo-treated patients. By Week 12, 6% of the
dupilumab cohort and 44% of the placebo cohort had experienced an
exacerbation, clearly demonstrating dupilumab's prevention of
ICS-withdrawal-induced exacerbations. Similar to the anti-IL-13monoclonal antibodies, dupilumab also suppressed TARC, eotaxin-3,
FeNO and IgE concentrations. The majority of patients treated with
dupilumab exhibited little or no change in blood eosinophil counts.
However, some patients also exhibited increases in blood eosinophil
counts, which resulted in an overall trend for a mean increase in blood
eosinophils at the end of the 12-week dupilumab treatment period
that did not reach statistical signiﬁcance (Wenzel et al., 2013a). In a
Phase IIb dose-ranging trial in patients with asthma uncontrolled with
medium- to high-dosage ICS/LABA were treated for 24 weeks with
200-mg or 300-mg dupilumab every 2 or 4 weeks or placebo (Wenzel
et al., 2016). Improvements in lung function and exacerbation rate
were greater for the dosages given every 2 weeks compared with the
other treatment groups for both the overall population and the sub-
groups with blood eosinophil counts either ≥300 or b300 cells/μL at
Week 12. For the patients who had received dupilumab every 2
weeks, the least-square mean difference versus placebo in FEV1 change
from baseline was 0.16 L–0.20 L. Risk reduction versus placebo for the
annualized severe exacerbation rate was 59.9%–67.6% (Wenzel et al.,
2016). Dupilumab is currently being evaluated in Phase III studies of pa-
tients with asthma (NCT02414854, NCT02528214).
Noteworthy observations from these studies were that patients not
on long-term OCS with baseline FEV1 reversibility ≥12% responded bet-
ter to anti-IL-13 mAb treatment than the overall population (Brightling
et al., 2015b). In addition, treatment with tralokinumab, lebrikizumab,
or dupilumab was more efﬁcacious (i.e., improvements in FEV1) for pa-
tients with increased blood eosinophil counts ≥240 to ≥300 cells/μL
(Piper et al., 2013; Hanania et al., 2015; Wenzel et al., 2016).
Interestingly, patients receiving anti-IL-13 or anti-IL-4Rα therapies
(tralokinumab, lebrikizumab, and dupilumab) exhibited moderately
increased blood eosinophil counts (Corren et al., 2011; Piper et al.,
2013; Wenzel et al., 2013; Hanania et al., 2015; Brightling et al.,
2015a). This ﬁnding may reﬂect inhibition of eosinophil-recruiting
chemokines by blocking IL-13 biological activity, reducing migration
of eosinophils from the blood to the lungs. Data regarding the effect of
anti-IL-13 therapy on tissue, sputum, and lavage eosinophils are eagerly
awaited (NCT02099656).
The absence of evidence for profoundperipheral eosinophil suppres-
sion in patients treatedwith anti-IL-13 and anti-IL-4Rα therapies points
to fundamental differences in their mechanisms of action compared
with anti-IL-5 and anti-IL-5Rα therapies. If so, then this observation
could point to only a limited overlapwith anti-IL-5/anti-IL-5R therapies.
The efﬁcacy of anti-IL-5 and anti-IL-5R therapies for asthma patients
with high concentrations of biomarkers for IL-13 pathway activation
suggests that further exploration may help to differentiate between
anti-IL-13 and anti-IL-5 therapies and provide a basis for co-
administration of these therapies in speciﬁc asthma subpopulations.
6.5. Other therapeutic antibodies
Anti-TSLP (AMG157/MEDI-9929, Amgen, AstraZeneca,MedImmune)
is a fully human anti-TSLPmAb inhibiting TSLP activity. TSLP is a cytokine
mainly produced from structural cells, including airway epithelial cells, in
response to pro-inﬂammatory stimuli. TSLP induces Th2 inﬂammation
through its activities on many cell types, of which the most prominent
are the induction of OX40L/OX40 signaling and the production of Th2
cytokines by dendritic cells, mast cells, ILC2 and CrTh2+ CD4+ T cells.
AMG157 attenuated most measures of allergen-induced early and late
asthmatic responses in an allergen-challenge study in patients with
mild atopic asthma. Treatment with AMG157 moderately suppressed
blood eosinophils over the course of the study and profoundly
decreased sputum eosinophils after allergen challenge (Gauvreau
et al., 2014). AMG157 is currently in Phase II studies in severe, uncon-
trolled asthma (NCT02054130).
Bertilimumab (Immune Pharma) is a fully human anti-eotaxin-1
mAb in development for asthma with Phase II trial results expected in
2016. Eotaxin-1 (CCL11) is a potent eosinophil chemoattractant that is
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receptor for eotaxin-1, but it is promiscuous and can be activated by a
wide range of chemokines. Although its expressionwas initially thought
to be limited to eosinophils, CCR3 is now recognized to be more widely
expressed (e.g., on basophils,mast cells, Th2 T cells). By binding to CCR3,
eotaxins-1, 2 (CCL24) and 3 (CCL26) recruit eosinophils to sites of
inﬂammation and activate them. Patients with acute asthma have ele-
vated CCL11 plasma concentrations comparedwith patients with stable
asthma (Lilly et al., 1999), and patients with asthma exhibit increased
expression of CCL11 and CCL24 in their allergic lungs (Ying et al.,
1999) and in their sputum (Yamada et al., 2000). Furthermore, patients
with atopic asthma have increased CCR3mRNA and protein expression.
Increased expression of CCR3 is associated with AHR in patients with
asthma (Ying et al., 1997). An anti-CCR3 mAb and small molecule
CCR3 antagonists suppressed airway eosinophilia in models of allergic
airway inﬂammation (Justice et al., 2003; Wegmann et al., 2007;
Komai et al., 2010). However, the ﬁrst clinical study of patients with
asthma with eosinophilic inﬂammation with a small-molecule oral
CCR3 antagonist, GW766994, achieved plasma drug concentrations
consistent with 90% receptor occupancy, but it did not signiﬁcantly
decrease eosinophil counts in blood or sputum. This ﬁnding has called
into question the potential for CCR3 antagonists to reverse established
airway eosinophilia in asthmatics (Neighbour et al., 2014). Historically,
several pharmaceutical companies have had programs to develop
antagonists to CCR3 or its activating chemokine eotaxin, but relatively
few of these are still active. Targeting of eotaxin-1 with bertilimumab
has the potential for redundancy with other CCR3-activating
chemokines, which is clearly a key issue for this approach. AXP-1275
(Axikin) and GW-766904 (GSK) are orally available, small-molecule
inhibitors of CCR3 reported to be in Phase II development for asthma.
Overall, the potential for eotaxin and CCR3 antagonists in the treatment
of asthma looks very uncertain.
Fig. 1b illustrates all the therapeutic antibodies discussed here and
their molecular targets and modes of action. The table captures their
properties (antibody formats and afﬁnities) and summarizes the effects
of these therapeutic antibodies on eosinophil concentrations and their
clinical efﬁcacies in patients with asthma.
7. Future directions for anti-eosinophilic therapies
Development of new therapeutic antibodies targeting asthma and
COPD with eosinophilic inﬂammation holds promise to provide much-
needed help for patients. In addition, arising from the advent of these
therapies, a number of areas are ripe for further exploration.
7.1. Biomarkers
As severe asthma is a heterogeneous diseasewith several inﬂamma-
tory phenotypes (Gauthier et al., 2015), identifying biomarkers to select
patients who aremost likely to gain clinical beneﬁt bymonoclonal anti-
body therapies that target speciﬁc cytokines or inﬂammatory pathways
is a useful strategy. Furthermore, pragmatic and easy-to-use sampling
methods, such as blood tests, facilitate biomarker use. For example,
methods for sampling the airways by induced sputum collection or
endobronchial biopsies are invasive and require specialized equipment
and trained personnel, often limiting their use to clinical research rather
than clinical practice. To evaluate blood biomarkers predictive of eosin-
ophilic inﬂammation in the airway, several studies have investigated
the correlations of different blood biomarkers with eosinophilic inﬂam-
mation in patients with asthma (Jia et al., 2012; Hastie et al., 2013;
Wagener et al., 2016). Relationships between blood biomarkers and
airway inﬂammation may vary, based on the patient populations
studied, assays applied, time and method of sampling, and medications
patients use. For example, some studies identiﬁed blood eosinophils as a
poor predictor of eosinophilic inﬂammation in the airways (Hastie et al.,
2013), while more recent studies suggest that blood eosinophils may begood predictors of eosinophilic inﬂammation of the airway in
asthmatics (Wagener et al., 2016). Establishing response to therapy in
clinical studies with patients stratiﬁed by biomarker high vs biomarker
low ultimately determines the usefulness and predictive utility of
biomarkers. To that end, elevated biomarkers such as IgE, circulating
eosinophils, or serum periostin/dipeptidyl peptidase-4 have already
been shown to predict improved treatment response to anti-IgE, anti-
IL-5/anti-IL-5Rα, and anti-IL-13 therapeutic antibodies, respectively
(Skiepko et al., 2014; Castro et al., 2014; Brightling et al., 2015a). How-
ever, none of thesemarkers alone is a perfect predictor of treatment re-
sponse, as they overlap with one another (Tran et al., 2016), and some
biomarkers may work best in the context of certain clinical characteris-
tics (e.g., more reversible airway disease, patient age at disease onset).
Theymay also vary over time andwith treatment (e.g., systemic cortico-
steroids) and, therefore, disease progression. As discussed above, eosin-
ophil degranulation productsmay offer an alternative approach, but this
has yet to be validated. Further, clinical research is required to improve
the use and predictability of such markers and to identify new bio-
markers that may be more predictive of molecular mechanisms in the
airway, and consequently clinical outcomes.
7.2. Early intervention and intervention
in patients with mild to moderate asthma
Children with severe asthma have persistent, steroid-resistant
pulmonary eosinophilia associated with signiﬁcant airway remodeling
(Bossley et al., 2012). Therefore, intervention with eosinophil-
targeting therapeutic strategies early in life may both provide immedi-
ate relief and have the potential to avoid irreversible structural changes
in the airways that could limit treatment responses later in life. For
patients with advanced disease, disease activity reﬂects damage as
well as inﬂammation. Consequently, any therapeutic intervention has
a substantial, potentially irreversible component to overcome. A similar
argument could be made for the treatment of adults with mild to
moderate asthma to prevent remodeling and accelerated decline in
lung function. There is indeed precedent for the successful application
of an “early intervention paradigm,” which comes from studies in
patients with rheumatoid disease. Patients with rheumatoid arthritis
who were treated at disease inception with an aggressive combination
of methotrexate and a TNF blocker responded to therapy rapidly, and
a signiﬁcantly greater percentage of patients achieved remission
(Emery et al., 2012; Emery, 2014).
In addition, infrequent administration of these parenteral therapeu-
tics may improve compliance in pediatric and adult patients with less
severe disease. Furthermore, the acceptable safety proﬁle of systemically
administered therapeutic antibodies in adult patients provides support
to expand clinical trials to pediatric patient populations and those
patients with less severe disease. Interestingly, evidence in preclinical
models has recently been published suggesting a role for eosinophils
in adipose tissue homeostasis (Wu et al., 2011; Qiu et al., 2014) and in
supporting plasma cell survival and promoting humoral responses
through their interactions with B cells (Chu et al., 2011; Chu & Berek,
2012). However, no observations from clinical studies targeting eosino-
phils have been made yet to corroborate these ﬁndings. Although this
discrepancy may be attributable to a difference between species,
patients should be monitored appropriately in ongoing clinical trials.
7.3. Expansion of anti-eosinophilic therapies to other indications
The acceptable systemic safety proﬁle of the anti-eosinophilic thera-
pies discussed in this reviewmay provide an upside for the treatment of
comorbidities outside the lung, such as nasal polyposis or eczema,
which are often associated with asthma. There is also opportunity to
provide beneﬁt for patients with eosinophilic esophagitis, chronic
rhinosinusitis with polyposis, hypereosinophilic syndrome, Churg-
Strauss syndrome, and eosinophilic gastrointestinal diseases, all of
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diseases in dire need of new treatment options. Clinical trials with
anti-IL-5 and anti-IL-5Rα therapies are already underway in some of
these indications.
8. Conclusions
For patients with severe asthma and COPDwith eosinophilic inﬂam-
mation, clinical symptoms are often poorly controlled despite the use of
high-dosage inhaled and systemic corticosteroids. Monoclonal antibod-
ies targeting cytokines and receptors implicated in the pathogenesis of
eosinophilic inﬂammation have emerged as potent adjunct therapies
providing additional beneﬁts for these patients. The approvals of
mepolizumab and reslizumab as add-on therapies for maintenance
treatment of patients with severe asthma and the development of
anti-IL-5R antibodies for patients with asthma and COPD with eosino-
philic inﬂammation will provide additional treatment options for sub-
groups of patients who have an inadequate or incomplete response to
corticosteroid therapy. Because of the speciﬁcity of these therapeutics,
they are generally well-tolerated with limited off-target adverse effects
(mainly injection-site reactions and limited immunogenicity). This
safety proﬁle could, eventually, allow their use in patients with less
severe disease, pediatric patients, and other eosinophilic indications.
The advent of a range of antibodies targeting different mechanisms
in asthma should enable progress toward the goal of personalized
medicine, in which existing biomarkers aid clinicians in matching each
biologic therapy to the patient population most likely to beneﬁt from
that treatment. Future directions for research should include discovery
of new biomarkers, exploration of combination therapies that target
multiple pathways, and recognition of the disease underlying patholo-
gies in additional patient subpopulations who might beneﬁt from
novel treatments.
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